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Cyclodextrins (CDs) are a series of natural cyclic oligosaccharides. The 
most widely used CDs consist of 6, 7, and 8 D(+)-glucose units connected by 
α-1,4-linkages, named α-, β-, and γ-CD, respectively. The torus structure of 
CDs is unique with hydrophilic outer surfaces and hydrophobic cavities. The 
hydrophobic cavities can form inclusion complexes with many hydrophobic 
drugs to alter their physical, chemical, and biological properties. Furthermore, 
the hydroxyl groups can be conjugated with cationic polymers for potential 
gene delivery. 
This thesis has four parts. In the first part, we present a literature review 
of cancer therapy especially chemotherapy, gene therapy, and a combination of 
drug and gene co-delivery. The properties of CD and CD-based drug delivery, 
targeted gene delivery, and co-delivery will be presented in this thesis. 
In the second part, we synthesized α-, β-, and γ-CD derivatives by 
conjugation with short-chain oligoethylenimine arms. These modified cationic 
cyclodextrin variants can form inclusion complexes with anticancer drug 
paclitaxel and significantly improve the physiochemical properties, such as 
solubility. The antitumor activity of paclitaxel in the inclusion complexes is 
still maintained. 




polymer containing a -cyclodextrin core and multiple oligoethylenimine arms. 
Folic acid was conjugated to the cationic molecules for effective target 
delivery and a biodegradable disulfide bond was incorporated between the 
cationic polymer and target group. The new CD-based cationic polymer, 
named γ-CD-OEI-SS-FA, had low cytotoxicity, and is able to target deliver 
DNA to specific tumor cells that overexpress folate receptors, as well as smart 
functions to recover and recycle folate receptors onto cellular membranes to 
facilitate continuous folate receptor mediated endocytosis to achieve very high 
levels of gene expression. 
In the fourth part, we investigated the synergistic/combined effect by 
co-delivery of drug and gene to fabricate more effective gene delivery systems. 
Paclitaxel formed inclusion complexes with previous synthesized cationic 
polymer γ-CD-OEI-SS-FA. The co-delivery system maintains the target effect 
and folate receptor recovery function of γ-CD-OEI-SS-FA. Moreover, the 
unique hydrophobic cavity of γ-CD was used to load paclitaxel with high 
loading efficiency and high stability and solubility in water. Co-delivery 
synergistic effect by delivery of tumor suppressor p53 gene was achieved. This 
co-delivery system could be an efficient strategy for potential cancer gene 
therapy. 
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CHAPTER 1 INTRODUCTION 
This thesis contributes to the synthesis of cyclodextrin-based cationic 
polymers and their application on drug and gene delivery for potential cancer 
therapy. In this chapter, the background information of cancer therapy, 
cyclodextrin-based polymers on drug delivery, and cyclodextrin-based 
non-viral vectors on gene delivery is discussed. In addition, we provide the 
scope and objective of our study. Finally, the contents and structure of this 
thesis are listed. 
1.1. Background Information 
WHO reported that cancer is one of the leading causes of death worldwide 
and 7.6 million people died because of cancer (around 13% of all deaths) in 
2008. Cancer therapy generally includes chemotherapy, radiotherapy, surgery, 
hormone therapy, immunotherapy, and gene therapy. All the cancer therapy 
methods have their advantages and disadvantages.  
Chemotherapy using anticancer drugs usually kills both tumor cells and 
normal cells, leading to serious side effects. Paclitaxel (PTX) is one of the 
most widely used drugs that can efficiently treat ovarian, breast, head and 
neck, and non-small-cell lung cancers.1, 2 The mechanism of PTX is to bind 
tubulin and promote tubulin polymerization and stabilization of microtubules 
 
Chapter 1. Introduction 
2 
against depolymerization.3, 4 Thus, PTX-induced microtubule stabilization 
leads to G2/M cell cycle arrest and cell death.5 The application of PTX usually 
hampers by its limited source and poor aqueous solubility.6-8 Structure 
modification of PTX and preparation of effective formulations with effective 
carriers are widely investigated to improve its physiochemical properties and 
anticancer capability. 
Gene therapy is the treatment of diseases using the genetic materials to 
specific cells of a patient,9 which has been greatly studied during the last two 
decades. Nowadays, design and synthesis of safe and effective non-viral 
vectors to carry and protect oligonucleotides for gene therapy has attracted 
great interest because of the superior properties of safety, low cytotoxicity, 
easy to be scale-up and structure modification.10 Cationic polymer is one of 
the most investigated non-viral gene delivery materials. Among of them, 
polyethylenimine (PEI) is one of the most prominent examples of cationic 
polymers that have been extensively studied as non-viral gene delivery 
vectors.11 The DNA polyplexes of PEI can avoid lysosomal trafficking and 
degradation after internalization into cells due to its buffering capacity.12 The 
application of PEI generally hinders due to its high toxicity induced by the 
aggregation and adherence on the cell surface.13-15 Structure modification of 
PEI with poly(ethylene glycol) PEG,16-18 polycaprolactone (PCL),19, 20 
cyclodextrin,21 and other formulations are widely investigated. 
Cyclodextrins (CDs) are a series of natural cyclic oligosaccharides, which 
consist by D(+)-glucose units linked by α-1,4-linkages. The unique structure 
of CDs is composed of hydrophilic outer surfaces and hydrophobic cavities. 
The hydrophobic cavities can include some hydrophobic drugs to alter their 
physical, chemical, and biological properties.22-24 Inclusion complexes 
between CD derivatives and PTX have already been greatly investigated in the 
last two decades to try to solve the undesired side effects induced by the 
cremophor formulation of PTX.25-31 CD derivatives, such as dimethyl-β-CD, 
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hydroxypropyl-β-CD, bridged dimers, have been greatly studied in the 
formation of inclusion complex with PTX for drug delivery. However, more 
stable and efficient CD-based carriers still need to be explored. 
Ligands with specific binding ability to cancer cells that overexpressed 
corresponding receptors are widely conjugated to gene delivery vectors for 
targeted delivery. Folic acid is a vitamin that has been greatly investigated in 
targeted drug and gene delivery, because many malignancies cells including 
the ovary, brain, kidney, breast, lung, and myeloid cells overexpress folate 
receptors.32 Preparation of folate-linked non-viral biocompatible polymeric as 
gene delivery vectors, such as cationic polymers, cationic lipids, cationic 
peptides, and so on has already been widely studied.33-35 Moreover, some 
folate-conjugated drugs have already entered clinic trials.36-40 
In addition, structure modification of drug and gene delivery carriers may 
induce the change of their physical and biological properties. Therefore, the 
choice of appropriate linker between carriers and delivery enhancing moieties 
is very important. A covalent disulfide bond is widely used as a linker in drug 
and gene delivery systems due to the unique properties that cleavage of the 
redox-sensitive disulfide linker can be adjusted by the large gradient between 
extracellular and intracellular environment. 
Combination therapy can modulate the different signaling pathways in 
cancer cells, so it is an effective and widely-used approach in cancer therapy. 
Drug and gene co-delivery has been approved to have the 
synergistic/combined effects in cancer therapy.41-46 
The application of CDs in gene delivery thanks to the active hydroxyl 
groups for further structure modification. Since the first publication of 
CD-conjugated cationic polymers for gene delivery by Mark E. Davisʹs 
group,47 CD based cationic polymers, especially CD-oligoethylenimine 
(CD-OEI), have been attracted great interests in gene delivery with 
combination the advantages of both CD and OEI. Our group reported a series 
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of cationic star polymers by conjugating oligoethylenimine (OEI) chains to 
α-CD as non-viral gene delivery vectors (Scheme 1.1).48, 49 These α-CD-OEI 
star-shaped polymers showed much lower cytotoxicity and excellent gene 
transfection efficiency that were comparable to or even higher than that of the 
well-studied branched PEI (25 kDa). However, the synthesized CD-based 
cationic polymer lacks of target groups which can enhance the gene delivery 
ability and minimize the dosage and cytotoxicity. Moreover, the hydrophobic 
CD ring provides possible application in drug delivery, which may further 
enhance the gene delivery and the synergistic effect of co-delivery. 
 
Scheme 1.1. Synthesis procedures of a-CD-OEI star polymers. 
1.2. Objective and Scope of Study 
This research studied the preparation of novel natural cyclodextrin based 
cationic polymers and their applications on drug and gene delivery. This study 
synthesized multi-functional cyclodextrin derivatives according to its 
interesting physiochemical properties. The inclusion complexes of 
cyclodextrin with guest molecules and the enhancement of drug properties and 
synergistic/combined effect on gene delivery were further explored. 
Specifically, the objectives of this research are: 
To prepare series of α-, β-, and γ-cyclodextrin derivatives conjugated with 
oligoethylenimine and to evaluate their ability to form inclusion complexes 
with anticancer drug for potential drug delivery. 
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a -cyclodextrin core and multiple oligoethylenimine arms with folic acid 
linked by a biodegradable disulfide bond for efficient targeted gene delivery. 
This study has expanded the strategy of FA-targeted delivery by combining the 
smart folate receptor-recycling function to achieve the significant 
enhancement of gene expression. 
To synthesize a gene delivery carrier by formation of inclusion complex 
between a folate-conjugated γ-cyclodextrin-oligoethylenimine with disulfide 
linker (γ-CD-OEI-SS-FA) and anticancer drug paclitaxel thanks to the 
hydrophobic cavity of cyclodextrin. Co-delivery of drug and gene shows 
synergistic/combined effect on gene delivery. 
1.3. Organization of the Thesis  
Encompassing the objectives discussed, the detailed research works about 
the cyclodextrin-based cationic polymers on drug and gene delivery is 
organized as the following chapters: 
Chapter 2: Literature review on the topic of cancer chemotherapy and gene 
therapy. The physiochemical and biological properties of cyclodextrin, the 
application of cyclodextrin (CD) in drug and gene delivery are involved. 
In addition, the target delivery and methods to improve drug delivery and 
gene delivery will be discussed. 
Chapter 3: Report on the synthesis of α-, β-, and γ-CD derivatives by 
conjugation with oligoethylenimine (OEI). These modified CD 
derivatives can form inclusion complexes with anticancer drug PTX and 
significantly improve the physiochemical properties, which has potential 
application as drug delivery carriers. 
Chapter 4: Synthesis of a new star-shaped cationic polymer containing a -CD 
core and multiple oligoethylenimine arms. Folic acid (FA) was conjugated 
for effective target delivery with a biodegradable disulfide bond between 
the cationic polymer and target group. The new γ-CD-OEI-SS-FA gene 
 
Chapter 1. Introduction 
6 
carrier had low cytotoxicity, and possessed capacity to target and deliver 
DNA to specific tumor cells that overexpress folate receptors, as well as 
functions to recover and recycle folate receptors onto cellular membranes 
to facilitate continuous folate receptor mediated endocytosis to achieve 
very high levels of gene expression. 
Chapter 5: Co-delivery of pDNA and Drug by formation of inclusion complex 
between paclitaxel and folate-grafted γ-CD-OEI with disulfide linker. The 
drug and gene co-delivery has synergistic effect and it could be an 
efficient strategy for potential cancer gene therapy. 
Chapter 6: Conclusion on the work done with possible future endeavours. 
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CHAPTER 2 LITERATURE REVIEW 
2.1. Cancer and Cancer Therapy 
Cancer is defined as a generic term for a large group of diseases that can 
affect any part of the body (World Health Organization, WHO). WHO reported 
that cancer is one of the leading causes of death worldwide and 7.6 million 
people died from cancer (around 13% of all deaths) in 2008. Among of them, 
lung, stomach, liver, colon and breast cancer cause the most cancer deaths 
each year (Figure 2.1). In addition, deaths from cancer worldwide are expected 
to continue rising, with an estimated 13.1 million deaths in 2030 (WHO global 
cancer statistics). The Singapore Cancer Registry provides information on 
cancer patterns and trends in Singapore that a total number of 51,657 incident 
cancer cases were diagnosed among the Resident population during the period 
2006-2010.1 Lung cancer and breast cancer caused the highest mortality rates 




Chapter 2. Literature Review 
11 
Figure 2.1. Illustration of worldwide cancer mortality rates (Referred from 
WHO GLOBOCAN 2008). 
2.1.1. Cancer Treatments 
Cancer therapy generally includes chemotherapy, radiotherapy, surgery, 
hormone therapy, and immunotherapy. Complete surgical resection is usually 
the first consideration for patients and is still the most effective method. 
However, surgery is often obstructed by several issues, such as potential 
wound infection, the limitation by the size and location of tumor, and possible 
tumor relapse. Radiotherapy usually kills both cancer cells and normal cells, 
resulting in long-term side effects such as fatigue and hair loss. A combination 
of surgery and radiotherapy is usually used in cancer treatment. But it is still 
difficult to control the re-growth and metastatic secondary tumor growth.2, 3 
Chemotherapy also faces the selectivity problem that the drugs kill both 
tumor cells and normal cells. Depending on the properties of different 
anticancer drugs, the drugs differ in their cytotoxic mechanisms and side 
effects. Integration of chemotherapy into a combined modality on cancer 
treatment is often used, such as chemotherapy plus surgery or radiotherapy. 
Moreover, treatment of cancers with a combination chemotherapy using two 
or more drugs simultaneously is also widely used in cancer therapy. 
2.1.2. Anticancer Drugs 
There are kinds of drugs commercially available for cancer chemotherapy, 
including doxorubicin, paclitaxel and docetaxel, fluorouracil, chlorambucil, 
methotrexate, cisplatin, and so on. These anticancer drugs are categorized into 
several groups depending on their different mechanism. 
Paclitaxel (PTX) is a diterpenoid natural product isolated from Taxus 
brevifolia with potential activity against ovarian, breast, head and neck, and 
non-small-cell lung cancers.4, 5 The structure of PTX displays in Figure 2.2. 
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Figure 2.2. Structure of paclitaxel. 
PTX promotes the polymerization of tubulin. The microtubule formed 
under PTX are every stable and dysfunctional, causing cell death by disrupting 
the normal tubule dynamics required for cell division and vital interphase 
process. 6-10 
One problem for PTX application is the limited source. Around four tree 
need to be sacrificed to produce 2 g of drug for one patient.11, 12 Another major 
problems is its low aqueous solubility.13 PTX is administrated by an infusion 
of cremophor EL (polyoxyethylated castor oil) containing 50% absolute 
ethanol. However, cremophor has been reported to cause severe 
hypersensitivity reactions and other side effects in animals and humans.14, 15 
Moreover, precipitation may be found on aqueous dilution. Therefore, the 
development of structure modification or alternate formulation for PTX 
delivery with good aqueous solubility and less side effects is necessary. There 
are various studies for PTX delivery include co-solvents, micelles, emulsions, 
liposomes, microspheres nanoparticles, pastes, implants, cyclodextrins (CDs), 
and so on. The enhancement ability by CD will be discussed in section 2.3. 
2.1.3. Gene Therapy 
Gene therapy is the treatment of diseases by the transfer of genetic 
materials into specific cells of a patient.16 Numerous disease-causing genes 
can be identified due to the development of molecular biology and the 
completion of the Human Genome Project.17 It is promising to treat genetic 
diseases such as haemophilia,18 muscular dystrophy,19 and cystic fibrosis20 by 
replacing the errant genes. In addition, gene therapy can also be developed for 
 
Chapter 2. Literature Review 
13 
cardiovascular, infectious diseases and cancer therapy by adding, correcting, 
and replacing of genes to amplify naturally occurring proteins, to alter the 
gene expression, or to produce cytotoxic proteins.17 
Both the genesis and evolution of cancers can be restrained by various 
tumor suppressive mechanisms. Effective tumor suppression needs to 
discriminate the normal and cancer cells. p53 is one of the most frequently 
delivered genes for effective cancer gene therapy, which plays a role as a 
prevailing guardian only in damaged or transformed cells, which induces cell 
growth arrest or apoptosis.21 The cells cannot control their growth if normal 
protective function of p53 is lost, resulting in rapid growth and progression 
toward malignancy.22, 23 Mover, around 50% of human cancers mutant or loss 
of p53 gene,24 and the loss of p53 may also result in resistance to radiotherapy 
or chemotherapy.25 Therefore, the reinstatement of wild-type p53 expression is 
a reasonable method for cancer therapy. 
2.1.4. Drug and Gene Co-delivery 
Combination therapy is an effective tool for cancer therapy due to the 
modulation of different signaling pathways in cancer cells with reduced 
toxicity. Moreover, combination therapy possibly overcomes the mechanisms 
of resistance and avoiding metastasis.26-28 It would have advantageous to 
deliver therapeutic genes and drugs in the same vehicle that both of them can 
be delivered to the same tissues thus maximizing the benefits of the 
combination. 29 
Co-delivery of DNA and anticancer drug, such as doxorubicin and PTX 
has shown great promise to achieve the synergistic/combined effects in cancer 
therapy.30-35 Yangʹs group reported the co-delivery of paclitaxel and plasmid 
DNA by cationic core-shell nanoparticles (Scheme 2.1) that improved gene 
transfection both in vitro and in vivo.32 Moreover, co-delivery of doxorubucin 
and p53 gene by micelles increased p53 mRNA expression level as well as 
cytotoxicity towards HepG2 cells.30 The presence of PTX would enhance gene 
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expression possibly due to its anti-mitotic function.36, 37 Although 
PTX-induced apoptosis is p53-independent,38, 39 the status of p53 may 
influence cell-cycle progression following mitotic arrest.40, 41 Nielsen et al 
reported adenovirus-mediated p53 gene therapy and PTX have synergistic 
effect in many cancer cell lines.42 
 
Scheme 2.1. Synthesis of cationic amphiphilic polymer P(MDS-co-CES).  
2.1.5. Gene Delivery Vectors 
Cancer gene therapy has obtained great attention over the past two 
decades as an alternative method to traditional chemotherapy.43, 44 Successful 
gene therapy needs to solve several problems, such as identification of a 
therapeutic gene and deliver the gene to specific cells in an efficient and safety 
method. Free oligonucleotide and DNA are rapidly degraded by nucleases and 
quick cleared by the mononuclear phagocyte system,45, 46 so the synthesis of 
effective gene delivery carriers to compact and protect genetic materials is 
necessary. 
The idea gene delivery vectors should have some specific characteristics: 
(i) target to specific cells and tissues; (ii) resistance to metabolic degradation 
and “escape” from the immune system; (iii) safety, the materials especially for 
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viral vectors should be non-toxic and minimal side effects; (iv) protective 
effect to keep the activity of genetic materials. 
Gene delivery vectors can be generally categorized into viral and 
non-viral vectors. The application of viral vectors is usually hindered by the 
toxicity, immunogenicity, and difficulty for large scale preparation.47 In 
contrast, non-viral vectors such as cationic lipid, polymers, dendrimers, and 
peptides, have advantages over viral vectors on the safety, potential for 
large-scale production, and ability to be readily functionalized, which attract 
increasing interests in gene delivery.48 However, non-viral vectors exhibit 
remarkable decrease of transfection efficiency since they need to overcome 
extra- and intracellular obstacles. So the synthesis of efficient non-viral 
vectors for successful gene delivery has attracted great interest. Cationic 
polymers can from complexes with DNA and avoid both in vitro and in vivo 
barriers which have been deeply investigated in the past decade. 
Except for the poor stability of free DNA in blood, cellular uptake of free 
DNA is usually hindered by its size and negative charge. Cationic polymers 
can carrier DNA by electrostatic interactions between the negative charged 
DNA and positive charged polymers. Cationic polymers usually compact 
multiple DNA molecules due to their strong interactions. The sizes of the 
DNA/polymers complexes mostly depend on the physical properties of the 
cationic polymers. For non-targeting cationic complexes, they can associate 
with the cell membrane through electrostatic interactions with the anionic cell 
surface proteoglycans. Evidence suggests that inhibitory of proteoglycans 
would inhibit the gene transfection.49, 50 Many interests have attracted to the 
target delivery by conjugation of receptor ligands to recognize the specific 
cells and tissues. The commonly used ligands include asialoglycoprotein, 
epidermal growth factor (EGF), folate, integrin, lactose, mannose, and 
transferring.51 After binding to the cell surface through the ligand/receptor 
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interactions, the DNA/polymers complexes are usually internalized into cell 
by clathrin-dependent endocytosis. 
Cationic polymers are widely researched as non-viral vectors due to their 
excellent properties for DNA delivery. Figure 2.3 shows some cationic 
polymers that have been widely studied as non-viral gene delivery vectors. 
Polyethylenimine (PEI) is often considered as the gold standard of gene 
transfection, which will be discussed in the next part. 
 
Figure 2.3. Selected cationic polymers as non-viral gene delivery vectors. 
Polyethylenimine 
Polyethylenimine (PEI) is one of the most prominent examples of cationic 
polymers.52 PEI and its derivatives have been extensively studied as non-viral 
gene carriers. The structures of branched and linear PEI are shown in Figure 
2.4. Branched PEI contains many amine groups, resulting in a high charge 
density. In addition, the high quantity of primary amines help the formation of 
polyplex, so branched PEI is more suitable for gene delivery compared to 
linear PEI. The increase of gene delivery ability of PEI was observed as 
increasing of its molecular weight from 600 to 70,000 Da, but accompanied 
with high toxicity.53, 54 The toxicity is induced by the aggregation and 
adherence on the cell surface, resulting in significant necrosis.55 Godbey et al 
reported that PEI forms a stable polyplex with DNA and this PEI/DNA 
x
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polyplex can move from endocytosis to nuclear entry.56 Approximately 80% 
of nitrogen atoms in PEI is unprotonated at physiological pH compared to less 
than 50% unprotonated nitrogen atoms at pH of 5.57 Therefore, the PEI 
polyplexes can avoid lysosomal trafficking and degradation after 
internalization into cells because of this buffering capacity. 
 
Figure 2.4. Structure of branched PEI (bPEI) and linear PEI (lPEI). 
Polyethylenimine Derivatives 
Significant research has focused on modification of PEI structure to 
improve the transfection efficiency and reduce the cytotoxicity. One of the 
most common methods is PEGylation, which reduces salt/serum affects by a 
hydrophilic poly(ethylene glycol) exterior. However, the reduced gene 
transfection efficiency is usually obtained because a decreased surface charge 
of PEG-PEI polymer that decrease the interaction with cell membrane.58 
Moreover, PEI-PEG conjugation with cell-targeting ligands still shows less 
internalization than unmodified PEI.59 Therefore, the PEGylation still hinders 
the gene transfection after cellular uptake. Conjugation of PEI amines with 
methyl and ethyl groups illustrated reduced gene transfection efficiency in 
both presence and absence of serum.60 
PEG-Polycaprolactone (PEG-PCL) is also widely studied. Shuai and 
co-workers demonstrated the synthesis of biodegradable amphiphilic 
PEI-g-PCL-b-PEG by grafting PCL-b-PEG onto PEI.61 These polymers 
showed low cytotoxicity and the gene transfection efficiency is comparable or 
even higher than the PEI (25 kDa). In vivo delivery of PCL-PEI conjugates 
showed that significantly higher transfection efficiency compare to the PEI (25 
kDa) through aerosol administration.62 
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Introduction of reducible disulfide bond or ester linkage can reduce the 
cytotoxicity of PEI. 63 PEI cannot be metabolized by cellular enzymes, so the 
body clearance of high molecular weight PEI is very slow. Low molecular 
weight PEI with reducible disulfide linker could assist uncoupling of PEI from 
DNA to enhance gene delivery (Scheme 2.2), and the cleaved low molecular 
weight PEI fragments could be easily cleared from the body.63-67 
 
Scheme 2.2. Conjugation of PEI with crosslinking reagents DSP and DTBP. 
Davisʹs group prepared CD-modified PEI derivatives that the cytotoxicity 
of both branched and linear PEI was reduced.68 The CD based modification of 
PEI will be discussed in section 2.4. 
2.2. Characteristics of Cyclodextrins 
Cyclodextrins (CDs) are a series of natural cyclic oligosaccharides. The 
most commonly used CD consist of 6, 7, and 8 D(+)-glucose units linked by 
α-1,4-linkages, named as α-, β-, and γ-CD, respectively. Figure 2.5 shows the 
toroidal structure of CDs with the primary hydroxyl groups at narrow rim and 
the secondary hydroxyl groups at the wide rim on the outer surface. In contrast, 
the inner wall of CDs mainly consists of methylene and methane groups. 
 








-CD 6 0.47 – 0.53 0.79 14.5
-CD  7 0.60 – 0.65 0.79 1.85
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As a result, CDs have a hydrophilic outer surface and a hydrophobic 
cavity. These properties make CDs form inclusion complexes with some guest 
molecules by their hydrophobic cavities.69-71 Therefore, the physical, chemical, 
and biological properties of guest molecules can be altered. These 
biocompatible, water-soluble CDs do not have immune responses and show 
low toxicity in animals and humans.72 CDs are usually used as solubilization 
and stabilization reagents for small molecules to improve the solubility, 
stability, and bioavailability due to their ability to accommodate hydrophobic 
drugs.73 CDs can also be applied in gene delivery thanks to the hydroxyl 
groups on the outer surface that offer opportunity for multiple modifications. 
2.2.1. The Physiochemical Properties of Cyclodextrins 
The superior natural properties of CD make it an excellent drug delivery 
candidate, which include: (1) many potential sites for chemical modification; 
(2) different CD has different cavity size suitable for different drug; (3) low 
toxicity and low pharmacological activity; (4) satisfactory water solubility; (5) 
protection of included or conjugated drugs from biodegradation.73 Nowadays, 
many CD derivatives, such as methylated CDs, hydroxylalkylated CDs, 
sulfated CDs, glucose conjugated CDs, anionic CDs, et al, have attracted great 
interest in their pharmaceutical application.74-78 
The solubility difference may be induced by the aggregation of CDs and 
the interaction with surrounding water molecules, together with the lattice 
energy in the solid state.79 Among of them, β-CD has particularly low water 
solubility due to the formation of intramolecular hydrogen bond,80 which 
inevitably limits its application in drug delivery. Generally, methylation and 
hydroxyalkylation of the hydroxyl groups of CDs can significantly improve 
their water solubility. Table 2.1 lists the structure of several CD derivatives 
and their enhanced solubility and chemical modification.81 
Table 2.1. Structural and physiochemical properties of selected CDs. 
 




The glucopyranose of CD ring has secondary hydroxyl groups at 2- and 
3-positions, and primary hydroxyl groups at the 6-positions. Among of them, 
the 6-OH is the most basic and more easily to be modified than 2- and 3-OH. 
Under normal conditions, an electrophilic reagent will attack the 6-positions 
that are most nucleophilic. However, reagents with high reactivity attack not 
only the primary hydroxyl groups at the 6-positions but also the secondary 
hydroxyl groups.82 
2.2.2. The Biological Properties of Cyclodextrins 
Cyclodextrins are quite stable in alkaline solution. However, they are 
hydrolyzed by strong acids to give linear oligosaccharides.71 Moreover, α- and 
β-CD are resistant to the metabolism in vivo, whereas γ-CD would more easily 
to be hydrolyzed.83 On the other hand, β-CD is hardly hydrolyzed84 and the 
branched β-CD will be excreted in urine. 
Natural CDs shows low toxicity and their oral metabolic fate has already 
been investigated.85 2-Hydroxypropyl-β-CD (HP-β-CD), 6-O-maltosyl-β-CD, 
and β-CD sulfate can be safely applied via parenteral administration.86 
Cyclodextrin n R Substance Solubility in water (mg/mL)
α-cyclodextrin 0 H 0 145
β-cyclodextrin 1 H 0 18.5
2-Hydroxypropyl-β-cyclodextrin 1 CH2CHOHCH3 0.65 >600
Sulfobutyletherβ-cyclodextrin 
sodium salt 1 (CH2)4SO3
-Na+ 0.9 >500
Randomly methylated β-cyclodextrin 1 CH3 1.8 >500
6-O-Maltosyl-β-cyclodextrin 1 Maltosyl 0 >1500
-Cyclodextrin 2 H 0 232
2-Hydroxypropyl--cyclodextrin 2 CH2CHOHCH3 0.6 >500
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Moreover, CDs can induce human erythrocytes to change their shapes. The 
hemolytic activity of CD derivatives follows the order of methylated β-CDs > 
β-CD > HP-β-CD ≈ G2-β-CD > α-CD > γ-CD > HP-γ-CD > SBE-β-CD.76, 87-90 
The acceptable daily oral intake of CDs is 1.4 g for α-CD, 0.35 g for β-CD, 10 
g for γ-CD, and 0.07 g for RM-β-CD.91 
2.3. Cyclodextrin on Drug Delivery 
CDs can improve the drug bioavailability due to their enhancement of 
membrane absorption and protection of biomolecules from non-specific 
interactions.92, 93 The reason for their membrane absorption enhancing 
properties is that the interaction with membrane will release certain membrane 
components and then destabilization and permeabilization.94 The ability of 
CDs to form inclusion complexes with guest molecules in both solution and 
solid states induces by the hydrophobic environment of the inner cavity 
(Figure 2.6). The physical, chemical, and biological properties of the guest 
molecules, such as drugs can be changed due to the interaction and protection 
of CDs. Since the first CD-based product prostaglandin E2/β-CD (Prostarmon 
ETM sublingual tablets) was marketed in 1976, many CD-containing products 
are marketed as kinds of formulations.72, 95 Generally, CDs are used to increase 
the solubility, stability and bioavailability.96-98 In addition, CDs can also 
reduce or prevent gastrointestinal and ocular irritation, and unpleasant smells 
or tastes.99, 100 
 
Figure 2.6. Illustrated formation of 1:1 CD-drug inclusion complex. 
Although α- and β-CD cannot be hydrolyzed by human salivary and 
pancreatic amylases,76 they can be fermented by the intestinal microflora. Oral 
administration of α-CD is generally safe without significant adverse effects.101, 
+
cyclodextrin Drug Inclusion complex
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102 However, the small cavity size of α-CD limits its pharmaceutical 
applications. β-CD is widely used in oral administration with low toxicity, 
although the low aqueous solubility and adverse effects limit its parenteral 
administration. Moreover, its derivatives, such as HP-β-CD, have low toxicity 
and much higher water-solubility than β-CD, and it is also well tolerated in 
humans.76, 89, 103, 104  
Table 2.2. Illustration of CD pharmaceutical products 
 
Drug/cyclodextrin Trade name  Formulation  Company
-CD
Alprostadil  Caverject Dual  i.v. solution  Pfizer
Cefotiam-hexetil HCl  Pansporin T  Tablet  Takeda
OP-1206  Opalmon  Tablet  Ono
PGE1  Prostavastin  Parenteral  Ono
solutions Schwarz
β-CD
Benexate HCl  Ulgut Capsule Teikoku
Lonmiel Shionogi
Cephalosporin)  Meiact  Tablet  Meiji Seika
Cetirzine  Cetrizin  Chewing tablet Losan Pharma
Chlordiazepoxide  Transillium  Tablet  Gador
Dexamethasone  Glymesason  Ointment Fujinaga
tablet
Dextromethorphan  Rynathisol  Synthelabo
Diphenhydramin and 
chlortheophyllin Stada-Travel  Chewing tablet Stada
Iodine  Mena-Gargle Solution  Kyushin
Meloxicam  Mobitil Tablet and suppository
Medical Union 
Pharmaceuticals
Nicotine  Nicorette  Sublingual Pfizer
tablets
Nimesulide  Nimedex  Tablets  Novartis
Nitroglycerin  Nitropen  Sublingual Nihon Kayaku
tablet
Omeprazole  Omebeta  Tablet  Betafarm
PGE2  Prostarmon E  Sublingual Ono
tablet Chiesi
Piroxicam  Brexin, Tablet, Aché
Flogene, suppository
Cicladon
Tiaprofenic acid  Surgamyl  Tablet Roussel-Maestrelli
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Table 2.2. (continued) 
Many drug failures are induced by the poor solubility, poor dissolution or poor 
permeability.105, 106 CDs provide a promising solution to improve the 
physiochemical properties of some drug candidates by formation of inclusion 
complexes. Table 2.2 illustrates some marketed CD products.81 
Inclusion complexes between CD derivatives and PTX have already been 
greatly investigated in the last two decades.107-113 As the smaller cavity size for 
α-CD (0.47 – 0.53 nm), it cannot form stable inclusion complex with PTX.107 
Sharma and co-workers investigated inclusion complexation between PTX and 
HP-β-CD, hydroxyethyl-β-CD, DM-β-CD, HP-γ-CD, and so on, indicating 
Drug/cyclodextrin Trade name  Formulation  Company
HP--CD
Alfaxalone
Cisapride  Propulsid  Suppository Janssen
Hydrocortisone  Dexocort  Solution  Actavis
Indomethacin  Indocid  Eye drop Chauvin
Itraconazole  Sporanox  Oral and i.v. Janssen
Mitomycin MitoExtra i.v. infusion Novartis (Europe) Novartis
Mitozytrex
SBE-β-CD
Aripiprazole  Abilify  im solution  Bristol-Myers 
Squibb; Otsuka 
Pharm
Maropitant  Cerenia Parenteral
Pfizer Animal Health
Voriconazole  Vfend  i.v. solution  Pfizer
Ziprasidone Geodon im solution  Pfizer
Zeldox
RM-β-CD
17β-Estradiol  Aerodiol  Nasal Spray  Servier
Cloramphenicol  Clorocil  Eye drop Oftalder
Insulin  Nasal spray  Spain
HP--CD
Diclofenac sodium 
salt Voltaren Eye drop solution Novartis
Tc-99 Teoboroxime CardioTec  i.v. solution  Bracco
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2000-fold or more increase of PTX solubility and maintain its cytostatic 
properties. However, the solubility of PTX limited by the CD concentration 
and high viscous was observed at high concentration. Moreover, these 
inclusion complexes were mostly not stable in aqueous solution and 
precipitation occurred upon dilution.108 
Table 2.3. Solubility of PTX in aqueous solutions with different CDs.  
 
Lee and coworkers investigated the PTX solubility enhancement by 
cyclosophoraoses, DM-β-CD, and HP-β-CD, whereas DM-β-CD has the best 
effect on the enhancement of solubility. Moreover, the interaction of PTX and 
DM-β-CD showed increase of fluorescence intensity compared to other 
molecules, indicating the possible interaction with the hydrophobic cluster site 
of C-ring in PTX molecule.114, 115 Alcaro et al. evaluated the interaction of 
PTX with β-CD, 2,6-DM-β-CD, and 2,3,6-trimethyl-β-CD. The progressive 
methylation of β-CD modulates the recognition of tumor cells. DM-β-CD is 
the most stable complex and all the inclusion complexes still have antitumor 
activity.116 Hamada et al. investigated the water solubility of PTX inclusion 
complexes using 11 CD derivatives. The solubility result is shown in Table 2.3, 





none 0.41 ± 0.05 1
-CD 0.72 ± 0.06 6 2
-CD 1.1 ± 0.08 6 3
-CD 0.93 ± 0.05 6 2
mono-6-O-maltosyl -CD 0.74 ± 0.04 6 2
mono-6-O-maltosyl -CD 1.2 ± 0.08 6 3
mono-6-O-maltosyl -CD 0.83 ± 0.07 6 2
heptakis-(2,6-di-O-methyl) -CD 0.41 ± 0.11 6 1
heptakis-(2,6-di-O-methyl) -CD 49 ± 0.52 6 120
heptakis-(2,3,6-tri-O-methyl) -CD 5.5 ± 0.11 6 13
random hydroxyethyl -CD 4.1 ± 0.14 6 10
random hydroxypropyl  -CD 7.8 ± 0.12 6 19
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which DM-β-CD has the highest effect. A tubulin assay illustrated that the 
DM-β-CD is 1.23-fold higher polymerization effect than PTX itself.111 Other 
studies also found the superior capability of DM-β-CD to form inclusion 
complex with PTX and maintain its antitumor ability.117-119 
 
Figure 2.7. Illustrated structure of β-CD dimer.  
Moser and coworkers demonstrated the synthesis of β-CD dimer by 
spacers with variant lengths. The length of the dimer in Figure 2.7 matches the 
distance between two benzoic acid residues of PTX. The affinity constants of 
the dimer compared to free β-CD are 107 l/mol. The inclusion complex of 
β-CD-dimer/PTX has a considerable time delay of incorporation into tumor 
cell.120, 121 As shown in Figure 2.8, Liu Yu and coworkers prepared CD dimer 
with OEI spacer which showed high PTX solubility enhancement (2 mg/mL). 
Structure with a ratio of 2:1 complex of PTX/CD dimer was confirmed by 1H 
NMR. 2D NMR showed H-3 and H-5 protons of CD cavities are strongly 
interacted with the ortho and meta protons of PTX A and B rings but weakly 
correlated with the C ring.109 Their further studies focused on adjusting the 
length of OEI linker. However, only long-tethered dimers can form inclusion 
complexes with PTX with satisfied water solubility, high thermal stability, and 
high antitumor activity.110 
 
Figure 2.8. Illustrated structure of bridged bis(β-CD).  
1.54 nm
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2.4. Cyclodextrin on Gene Delivery 
2.4.1. Cyclodextins as Gene Delivery Enhancers 
The gene transfection efficiency can be improved by the addition of CD 
and its derivatives as formulation excipients. Roessler et al reported that the 
substituted β-CDs interact with DNA complexes with polyamidoamine 
(PAMAM) dendrimers.122 Inclusion of β-CD helps to form smaller and more 
evenly distributed particles. In vitro CAT expression can be enhanced 
approximately 200-fold when β-CD was added. Pulmonary gene therapy 
systems with addition of absorption enhancer DM-β-CD benefit to the particle 
morphology and size distribution.123 The gene transfection is also increased in 
comparison to the unmodified powder. The application of CDs to enhance 
stability of DNA/polymer complexes and gene transfection efficiency has also 
been reported using PLL/hyaluronic acid (HA) system.124, 125 
2.4.2. Cyclodextrin-based Polymers for Gene Delivery 
In 1999, Mark E. Davisʹs group firstly reported the synthesis of 
CD-conjugated cationic polymers for gene delivery.126 Scheme 2.3a illustrates 
the synthetic procedure of CD-conjugated cationic polymer. The synthesized 
CD-based polymers illustrated lower cytotoxicity and the in vitro gene 
transfection is comparable to the PEI and lipofectamine. Then a series of 
research work was investigated to discuss the relationship between the gene 
transfection efficiency and the structure of the CD-based cationic polymers. 68, 
72, 127-134 Structure-activity relationship (SAR) studies draw a conclusion that 
these water-soluble CD-conjugated polymers with low molecular weight 
(around 10 kDa, degree of polymerization, 5 – 8) are the optimal structures 
with high gene transfection ability and low cytotoxicity. 
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Scheme 2.3. Synthesis of cyclodextrin-containing polycation (CDP, a) and the 
imidazole-terminated variant (CDPim, b).  
As shown in scheme 2.3b, the imidazole groups were conjugated to the 
termini of CDP with pH buffering capacity.135 This buffering capacity may 
enhance the ability to escape the endocytic pathway. Although the exactly 
mechanism for the enhancement of gene transfection efficiency of CDPim is 
not clear, the imidazole-containing variant CDPim showed significant 
improvement in gene delivery efficiency. In this work, the simple modification 
of non-viral gene delivery vectors can impart multiple functions. 
Our group reported a series of cationic star polymers by conjugating 
oligoethylenimine (OEI) chains to α-CD as non-viral gene delivery vectors 
(Scheme 2.4).136, 137 These α-CD-OEI star-shaped polymers showed much 
lower cytotoxicity and excellent gene transfection efficiency that were 
comparable to or even higher than that of the well-studied branched PEI (25 
kDa). 
 
Scheme 2.4. Synthesis of -CD-OEI star-shaped polymers. 
Huang et al synthesized low molecular weight PEI conjugated HP--CD 
and HP--CD that had low cytotoxicity and 1.5 – 1.7 fold higher gene 
transfection efficiency than PEI in SKOV-3 cells.138-140 Improved transfection 
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usually over-expresses on the surface of some cancer cells.141 The synthesized 
β-CD-PEI-folate polymer has efficient gene transfection in various cancer cell 
lines with low cytotoxicity, and the effect is higher than folate-free β-CD-PEI 
polymer (Scheme 2.5a). Similarly, MC-10 oligopeptide with targeting ability 
to the human epidermal growth factor receptor was conjugated to HP--CD, 
and the polymer HP-γ-CD-PEI-P (Scheme 2.5b) expressed low cytotoxicity 
and high gene transfection efficiency both in vitro and in vivo.142 Animal 
studies using a therapeutic IFN-α gene enhanced the antitumor effect on 
tumor-bearing mice in comparison with PEI (25 kDa). 
 
Scheme 2.5. Synthesis of β-CD-PEI-FA (a) and HP-γ-CD-PEI-P (b).  
“Click chemistry” has been employed in the synthesis of -CD-containing 
cationic polymers in gene delivery.143-145 Srinivasachari and Reineke 
synthesized -CD oligoethyleneamine variants using 1,3-dipolar cycloaddition 
of a diazido -CD and α,ω-dipropargylated oligoethyleneamine (Scheme 
2.6).143 Polymers with longer oligoethyleneamine have more effective 
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Scheme 2.6. Synthesis of the -CD-containing cationic polymers by click 
chemistry. 
Taking advantage of the ability of CDs to form inclusion complexes with 
hydrophobic molecules, the host-guest structure between poly-CDs and 
amphiphilic connector (DC-Chol or adamantane derivative Ada2) has been 
prepared.146 The surface charge of the polymers can be easily adjusted by the 
addition of connector which the cationic part towards outside. There is 2-fold 
higher gene transfection efficiency of the poly-βCD/DC-Chol inclusion 
complex than the single DC-Chol. The authors further studied the properties of 
inclusion complexes between poly-CD and other cationic polymer, such as 
the cationic surfactant n-dodecyltrimethylammonium chloride (DTAC) and 
other cationic adamantane derivatives.147, 148 
Davis and coworkers prepared inclusion complex between βCD-containing 
cationic polymers and adamantane-modified PEG that the PEGylation makes 
the DNA polyplexes stable in physiological conditions, although their 
luciferase expression is slightly reduced.149 In addition, the PEGylation 
variants show significantly differences in particle morphology and cellular 
uptake since the PEG moieties prevents particles from aggregation and 
non-specific interactions with biological component. Targeted delivery was 
endowed using adamantane-PEG conjugated with ligands.150 Galactosylated 
βCD-containing cationic polymers selectively target to hepatocytes through 
the asialoglycoprotein receptor. Transferrin (Tf) is a well-known ligand for 
tumor targeted delivery because of the upregulation of transferring receptors in 
many cancer cells. The Ad-PEG/Ad-PEG-Tf included cationic CD polymers 
more efficiently deliver pDNA and siRNA than the non-targeted particles.151, 
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152 The in vivo study demonstrated these transferring-modified, CD-based 
cationic polymers are able to protect and selectively deliver DNAzyme153 or 
small interfering RNA (siRNA)154-156. In 2008, a targeted therapeutic agent 
CALAA-01 (Calando Pharmaceuticals) is on the stage of phase I clinical trials. 
The agent is designed to inhibit tumor growth and/or reduce tumor size. The 
active ingredient is a small interfering RNA (siRNA) that inhibits tumor 
growth through RNA interference to reduce expression of the M2 subunit of 
ribonucleotide reductase (R2). CALAA-01 consists of four components: (i) 
siRNA for therapeutic ingredient; (ii) CD-based cationic polymer as carrier; 
(iii) PEGylation as stabilizing agent; (iv) Ad-PEG-Tf as targeting moiety 
(http://www.clinicaltrials.gov/ct2/show/NCT00689065). The structure has 
been displayed in Figure 2.9. A specific gene inhibition was induced by 
systematical administration of siRNA to a human.157 
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2.5. Cyclodextrin-based Polyrotaxanes for Drug and Gene 
Delivery 
The structure of polyrotaxane includes an appropriate axle, macrocycle 
wheels threaded on the axle, and bulky end-caps on the end of axle to avoid 
the slippage of macrocycle wheels. One of the specific features in 
polyrotaxanes is the absence of covalent bond between cyclic compounds and 
the polymeric chains. These special structures have attracted tremendous 
interest because of their unique structures as well as their potential as building 
blocks for lots of functional nanomaterials. Since the first synthesis of 
polyrotaxanes with α-cyclodextrin (α-CD) rings threaded over a polymer chain 
(Figure 2.10),158, 159 supramolecular architectures have greatly intrigued 
researchers due to their unique structures and promising properties on 
electronics160-162 and biomaterials applications, especially in the area of drug 
and gene delivery.163-168 
 
Figure 2.10. Demonstration of CD and polyrotaxane: (a) structure of α-CD, (b) 
synthesis of polyrotaxane from α-CD and PEO-diamine.158 
This kind of polyrotaxane is fascinating and very promising for 
drug-conjugating delivery due to several unique structural characteristics. 
Firstly, CDs have many hydroxyl groups that could be easily modified by 
chemical reactions, allowing the conjugation of bioactive agent onto the CD 
rings. Secondly, self-assembled polyrotaxanes have highly mobility of CD 
rings that can rotate around the polymer chain. This flexibility is expected to 
enhance multivalent ligand-receptor interaction, and is promising for 
applications on drug/gene delivery and tissue engineering.168, 169 Thirdly, CDs 
can dethread through the polymer chain when the bulky end-caps are cleaved, 
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polyrotaxanes consist of multiple OEI-grafted CDs threaded on polymer 
chains were attractive non-viral gene carries due to their low cytotoxicity, 
strong DNA binding ability, and high gene delivery capability.168, 171 Generally, 
thanks to their biocompatibility, flexibility and easily to be modified, 
polyrotaxanes have attracted much attention as vectors for drug and gene 
delivery. 
Table 2.4. List of generally used polymers and corresponding CDs 
 
The cavity size of different CDs and cross-sectional areas of the polymer 
chains are important factors for the formation of inclusion complexes between 
Polymer Formula CD Threaded
Poly(ethylene glycol) -CH2CH2O- 
Poly(propylene glycol) -CH2CH(CH3)O- 







Nylon 6 -NH(CH2)5CO- 









Poly(L-lactic acid) -OCH(CH3) 
Viologen polymers -N+C5C4-C5H4N+- 
Ionene polymers -N(CH3)2(CH2)n- 
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polymers and CDs. Table 2.4 lists the commonly used polymer axles and 
corresponding CDs for the formation of inclusion complexes.172 
Recently, growing attention has been attracted to the synthesis of 
inclusion complexes between CDs and block copolymers such as 
PEO-PPO-PEO triblock copolymers. PEO can form crystalline 
polypseudorotaxanes with smallest α-CD, but not with larger β-CD.173, 174 It is 
assumed that the PPO chain was too large to penetrate the inner cavity of 
α-CD. Larger β-CD would selectively thread the middle PPO block to form a 
polyrotaxane,175, 176 whereas α-CD selectively includes the flanking PEO 
blocks.177-179 Our group has already synthesized lots of polyrotaxanes between 
PEO-PPO-PEO triblock copolymers and α- or β-CD for application of 
hydrogels and cationic polyrotaxanes on drug and gene delivery.168, 177, 180-182 
On the other hand, CD-based polyrotaxanes could be widely applied as 
drug delivery systems by conjugating drugs or functional proteins onto the CD 
rings. Because CD rings threaded on polyrotaxane are movable along the 
polymer chain, this property contribute to the multivalent interaction and 
targeting delivery.183 For example, a polyrotaxane consisting of 
lactoside-CD-polyviologen conjugated polyrotaxane was investigated for its 
ability to inhibit galectin-1-mediated T-cell agglutination. Due to the rotating 
properties, the polyrotaxane showed an enhancement for the agglutination.184  
Furthermore, as compared to biodegradable hydrogel matrices for drug release, 
drug-conjugated biodegradable polyrotaxane can be advantageous in both 
controlling the drug release by degradation rate of terminal group and the 
number of CDs threaded onto the biodegradable polymer, and the dethreading 
of CDs modified with appropriate drugs may enhance drug permeation across 
biological barriers. The first example of biodegradable polyrotaxanes was 
reported in 1995.185 The supramolecular assemblies were formed between 
α-CD and PEO chain, capping with L-Phe via biodegradable peptide linkages. 
The in vitro release study shows that HP-α-CD can be released when either of 
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two terminal peptides was cleaved, and the rate of degradation can be 
controlled by changing the degree of hydrophobicity of the α-CDs.186 
Yang et al demonstrated the application of polyrotaxane-based delivery 
system for transport of anti-cancer drug doxorubincin (DOX). DOX was 
chemical conjugated to the polyrotaxane via hydrolysable linkage, which can 
be hydrolyzed and release DOX for cancer therapy. In addition, a 
cell-penetrating low molecular weight protamine (LMWP) peptide was further 
attached to the terminal of polymer chain in order to facilitate the intracellular 
uptake of tumor cells. The LMWP-PR-DOX conjugates illustrated sustained 
release of DOX over a period of greater than four days.187 
Thanks to the advantages of PEO-PPO-PEO triblock copolymer, 
polyrotaxane between EO13PO30EO13 copolymer and β-CD was prepared and 
capped with TNBS (Scheme 2.7). Then different lengths of OEI chains were 
linked to the β-CD rings to form cationic polyrotaxanes, which illustrated 
efficient gene delivery and much lower cytotoxicity than PEI (25 KDa). The 
spare PEO segment allows efficient link of OEI chains, and the OEI-grafted 
CD rings can freely move along the polymer chains, resulting flexibility for 
efficient complexation with DNA. The OEI chains with many primary and 
secondary amines are also beneficial for interaction with DNA and/or cell 
membranes.168 Applications with other systems such as OEI-grafted α-CD 
threaded on PEO chains,188 as OEI-grafted α-CD threaded on poly[(ethylene 
oxide)-ran-(propylene oxide)] (P(EO-r-PO)) random copolymer chains,163 
pentaethylenehexamine-grafted α-CD threaded on PPO-PEO-PPO triblock 
copolymer,171 different lengths of OEI-grafted β-CD threaded on 
PEO-PPO-PEO triblock copolymer182 all displayed strong DNA binding 
ability, low cytotoxity, and high gene delivery capability as a high potential on 
non-viral gene delivery carriers in cancer therapy. 
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Scheme 2.7. Synthesis procedures and structures of cationic polyrotaxanes with 
multiple OEI-grafted β-CD rings.168 
Yui and coworkers synthesized a series of aminoethylcarbamoyl 
(AEC)-polyrotaxanes between α-CD and PEG.189 Further preparation of 
polyrotaxanes employed dimethylaminoethyl (DMAEC)-modified α-CD 
threaded onto PEG chain capped with benzyloxycarboxyl tyrosine via 
biocleavalbe disulfide linkages.190, 191 This system was found to exhibit 
sufficient cleavage of disulfide linkages, as a result of the rapid endosomal 
escape and pDNA release. Furthermore, the polyplex with lowest number of 
DMAEC exhibited a much faster pDNA release in cytoplasm. Thus the 
transfection activity was related to an appropriate timing for DNA release and 
high transfection and stability can be achieve by optimizing numbers of 
DMAEC.192 
2.6. Target Delivery 
There are generally two methods to develop tumor-targeted therapies.193 
First is selectively block novel pathways or proteins that emerged or 
overexpressed in malignant cells but not needed to normal cells. Second 
strategy is the using of ligands with specific binding ability to receptors that is 
overexpressed on the malignant cells. The commonly used ligands include 
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antagonists and agonist, peptide hormones, oligosaccharides, oligopeptides, 
and vitamins.197-202 
2.6.1. Overview of Folic Acid and Folate Receptor 
Folic acid is a vitamin essential for biosynthesis of nucleotide bases. 
Folate receptor (FR) is a glycosylphosphatidylinositol (GPI)-linked membrane 
glycoprotein with high affinity folate binding ability.203 Many malignancies 
cells including of the ovary, brain, kidney, breast, lung, and myeloid cells 
overexpress folate receptors which rendered folate an attractive candidate for 
tumor-specific drug delivery.204 Moreover, the density of FR increases as the 
caner worsens. In contrast, FR on the normal cell is not easy to access due to 
its location on the apical membrane of polarized epithelia. 
FRs are significantly upregulated on tumor cells, so the folate-conjugated 
therapeutic agents can reduce the side effects and enhance the potency against 
tumor cells in comparison with the non-targeted cells.205, 206 Several 
folate-conjugated drugs have already entered clinic trials.207-211 
2.6.2. Folate-targeted Gene Therapy 
Great effort has been devoted to prepare folate-linked non-viral 
biocompatible polymeric gene delivery vectors, such as cationic polymers, 
cationic lipids, cationic peptides, and so on.193, 212, 213 PEI has inherent 
endosomal lytic activity, so PEI can not only condense DNA but also 
osmotically lyse its entrapping endosomes.214 The application of PEI usually 
hinders by its high toxicity from non-specific uptake. Directly conjugation of 
folate to PEI did not significantly alter the transfection efficiency.215 However, 
it can greatly enhance the gene transfection of PEG-modified PEI whereas 
PEGylation showed reduced cellular uptake and a partial inhibition of gene 
delivery. Benns et al. reported the synthesis of folate-PEG-folate-grafted-PEI 
(FPF-g-PEI) for targeted gene delivery.216 As a result, conjugation of FPF to 
PEI can reduce the toxicity and enhance gene expression. 
 
Chapter 2. Literature Review 
37 
2.6.3. Factors Affecting Folate-targeted Delivery 
Several factors would affect the folate-mediated targeted gene delivery in 
vivo: (i) endogenous folate in systemic circulation potentially blocks FR 
binding; (ii) the size of folate-conjugated vectors may preclude glomerular 
filtration; (iii) folate conjugate should escape the vasculature and intratumoral 
diffusion; (iv) the FR expression on tumor cells might be not sufficient.213  
2.7. Redox-Sensitive Carriers 
Introduction of target group, delivery-enhancing molecules, or functional 
moiety to drug and gene delivery systems has become an efficient approach to 
enhance the capability of drug and gene delivery systems. Structure 
modification may result in alternation of its cytotoxicity, pharmacokinetics, 
dynamics, and metabolism. In addition, the properties of linker between drug 
and the delivery enhancing entities significantly influence the successful 
application of drugs. Various redox-sensitive biodegradable cationic polymers 
have been employed in gene delivery. In comparison to hydrolytically 
degradable cationic polymers that the hydrolysis rate is proportional to the pH 
of environment, the redox-sensitive polymers are pretty stable under 
physiological conditions and rapid degradation occurs in the cytosol due to the 
thio-disulfide exchange by the high concentration of glutathione. On the one 
hand, the multi-functional polymers can be degraded into small fragments to 
alleviate accumulation of high molecular weight cationic polymer and the 
subsequent cytotoxicity. On the other hand, the degradation helps to efficient 
intracellular release of DNA or siRNA.217 
The design of redox-sensitive polymers usually involves incorporation of 
a covalent disulfide linker (–S–S–). Figure 2.11 lists some disulfide-containing 
cross-linking agents that are widely used in disulfide chemistry.217 The unique 
properties of disulfide bond render it particularly attractive in delivery systems: 
(i) the covalently bonded disulfides can be synthesized by oxidation of 
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sulfhydryls and the reversible reduction occur in the presence of reducing 
agents such as dithiothreitol (DTT), β-mercaptoethanol, and glutathione 
(GSH); (ii) the large gradient in reducing potential between extracellular (GSH 
concentration 2 – 20 μM) and intracellular (GSH concentration 0.5 – 10 mM) 
melieu makes disulfide linker intriguing as a smart delivery tool. 
 
 
Figure 2.11. Selective disulfide cross-linking agents.  
The application of disulfide bonds for delivery of macromolecular drugs 
has been reported in vitro and in vivo. The first antibody-targeted anticancer 
drug with disulfide linker Gemtuzumab Ozogamicin (Mylotarg) has been 
approved by FDA.218 Recently, more non-viral vectors with disulfide linker to 
promote DNA or siRNA delivery have been studied. 
Many target moieties hinder effect unpacking of gene vector due to their 
large size. Therefore, the strategy to remove the target groups inside cells is 
very important. Taking advantage of the redox-sensitive disulfide bond, the 
application of disulfide linkage between gene delivery vector and target group 
is a promising tool to solve this problem. Muratovska et al. reported the 
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attachment of membrane-permeant peptide (MPP) to siRNA with a disulfide 
linker. The peptide facilitates the transport across the cell membrane, and the 
bioactive siRNA was released after reduction of disulfide bond in the 
cytoplasm. The penetratin- or transportan-siRNA conjugates constitutively 
expressed luciferase and silenced GFP genes in a high proportion of cells of 
different types.219 Similarly, a molecular conjugate of asialoglycoprotein 
(ASGP) and antisense oligonucleotide using disulfide linker were found to 
significantly increase the effect of antisense oligonucleotides in vitro. The 
number of targeting ligands could be adjusted by the amount of linker.  
The reduction-sensitive biodegradable polymers are able to triggered 
deliver bioactive molecules including DNA, siRNA, antisense oligonucleotide, 
proteins, anticancer drugs, et al, especially for the systems that required to be 
stable in circulation and rapid degradation inside cells. 
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CHAPTER 3 SOLUBILITY AND ANTITUMOR 




Paclitaxel (PTX) is a diterpenoid natural product isolated from Taxus 
brevifolia with potential activity against ovarian, breast, head and neck, and 
non-small-cell lung cancers.1, 2 PTX is an antimicrotubule agent that promotes 
the polymerization of tubulin. The formed microtubules under treatment of 
PTX are every stable and dysfunctional, resulting in cell death by disrupting 
the normal tubule dynamics that is required for cell division and vital 
interphase process.3-7 
One of the major problems for PTX application is its low aqueous 
solubility.8 PTX is administrated by injection or infusion with cremophor EL 
(polyoxyethylated castor oil) containing 50% absolute ethanol for clinical 
application. However, cremophor has been reported to cause severe 
hypersensitivity reactions and other side effects in animals and humans.9, 10 To 
circumvent the application of cremophor, many approaches include micelles, 
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emulsions, liposomes, microsphere nanoparticles, and cyclodextrins (CDs), 
etc. have been investigated.11, 12 
CDs are a series of natural cyclic oligosaccharides composed of 6, 7, and 
8 D(+)-glucose units connected by α-1,4-linkages, named α-, β-, and γ-CD, 
respectively. The hydrophobic cavity of CDs allows formation of inclusion 
complexes with poorly water soluble drugs to increase their solubility, 
dissolution, and bioavailability.13 CDs can improve the drug bioavailability 
through the enhancement of membrane absorption and protection of 
biomolecules from non-specific interactions.14, 15 For a variety of reasons, CDs 
can be chemically or enzymatically modified their hydroxyl groups to further 
improve their aqueous solubility and other physical properties.16, 17 Some CD 
derivatives, such as (2-hydroxylpropyl)-β-CD (HP-β-CD) can be 
administrated to humans with high dose.18, 19  
Since the first CD-based product prostaglandin E2/β-CD (Prostarmon ETM 
sublingual tablets) was marketed in 1976, many CD-containing products are 
marketed as kinds of formulations.20, 21 Inclusion complexes between 
cyclodextrin derivatives and PTX have already been greatly investigated in the 
last two decades. As the smaller cavity size for α-CD (0.47 – 0.53 nm), it 
cannot form stable inclusion complex with PTX.22 The naturally β- and γ-CD 
showed 12-fold and 50-fold increase of PTX solubility, which was too low for 
administration. Sharma and co-workers investigated inclusion complexation 
between PTX and HP-β-CD, hydroxyethyl-β-CD (HE-β-CD), dimethyl-β-CD 
(DM-β-CD), HP-γ-CD, and so on, indicating 2000-fold or more increase of 
PTX solubility and maintain its cytostatic properties. However, the solubility 
of PTX was determined by the concentration of CD and high viscous was 
observed at high concentration. Moreover, these inclusion complexes were 
mostly not stable in aqueous solution and precipitation occurred upon 
dilution.23 DM-β-CD has also been proved to be one of the most effect 
solubilizers for PTX delivery with satisfactory antitumor activity by other 
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researchers.24-30 Uncomplexed DM-β-CD and HP-β-CD had a maximum 
tolerated dose (MTD) at doses of 2 g and 5 g CD/kg body weight respectively, 
and studies showed that the applications of taxane formulation need to reduce 
the toxicity of the CD carriers.23 Moser and Liuʹs groups investigated β-CD 
dimers for delivery of PTX that illustrated high water solubility, high thermal 
stability, and high antitumor activity.31-34 However, the synthesis and 
purification of the β-CD dimers is difficult which may limit their applications. 
 
Figure 3.1. Illustrated structure of paclitaxel and OEI-grafted cyclodextrins. 
Herein, we report the convenient structure modification of α-, β-, and 
γ-CD by different lengths of oligoethylenimine (abbreviated as CD-OEI, 
Figure 3.1) to further improve their water solubility and encapsulation ability. 
Moreover, the antitumor activity of the CD-OEI/PTX inclusion complexes 
was studied. 
3.2. Experimental Section 
3.2.1. Materials 
α-, β-, γ-CD, and 1,1'-carbonyldiimidazole (CDI) were purchased from 
Tokyo Chemical Industry Co. Ltd (Tokyo, Japan). Paclitaxel (PTX) was 
purchased from LC Laboratories Ltd (MA, USA).  Ethylenediamine (OEI-1), 
bis(2-aminoethyl)amine (OEI-2), and dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich. D2O used as solvents in the NMR 
measurement was obtained from Cambridge Isotope Laboratories, Inc. 
(Andover, U.S.A.). 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazodium 
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3.2.2. Synthesis 
The synthesis procedures of α-, β-, and γ-CD-OEI derivatives and their 
inclusion complexes with PTX are shown in Scheme 3.1. The following 
describes the detailed synthesis of γ-CD-OEI-2 and γ-CD-OEI-2/PTX as 
typical examples. 
 
Scheme 3.1. Synthesis of α-, β-, and γ-CD-OEI/PTX inclusion complexes 
N-(2-aminoethyl)-2-aminoethyl-carbamoyl-γ-cyclodextrin (γ-CD-OEI-2): 
To a solution of CDI (1.3 g, 8.0 mmol) in anhydrous DMSO (15 mL) was 
added dropwise a solution of γ-CD (650 mg, 0.5 mmol) in anhydrous DMSO 
(10 mL) during 30 min. After stirring for 4 hours, the solution was added 
dropwise into a mixture of THF/Et2O (100 mL/200 mL). The white precipitate 
was collected by centrifuge and dissolved into 20 mL of fresh anhydrous 
DMSO. Then the solution was added immediately by dropwise into a solution 
of ethylenediamine (960 mg, 16 mmol) in DMSO (10 mL) during 30 min. The 
mixture was then stirred at room temperature for an additional 1 day. The 
mixture was added into Et2O (160 mL) and the white precipitate was 
collected. Further purification by sephadex G50 column with water as eluent, 
freeze dried for 2 days at –87 ºC and 0.25 mbar to yield a white solid (yield, 
88%). 1H NMR: (400 MHz, D2O): δ 5.03 (brs, 8 H, H-1 of γ-CD), 2.98 – 4.56 
(m, 61 H, H2-6 of γ-CD, -OCONHCH2-), 2.34 – 2.98 (m, 40 H, -CH2CH2N-). 
2-Aminoethyl-carbamoyl-α-CD (α-CD-OEI-1): white solid (yield, 85%). 
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H, H2-6 of -CD, -OCONHCH2- of amine), 2.50 – 2.85 (m, 10.4 H, 
-CH2CH2NH-). 
N-(2-aminoethyl)-2-aminoethyl-carbamoyl-α-cyclodextrin (α-CD-OEI-2): 
white solid (yield, 81%). 1H NMR: (400 MHz, D2O): δ 5.15 (s, 6 H, H-1 of 
-CD), 2.87 – 4.52 (m, 46 H, H2-6 of -CD, -OCONHCH2- of amine), 2.40 – 
2.87 (m, 31 H, -CH2CH2NH-). 
2-Aminoethyl-carbamoyl-β-CD (β-CD-OEI-1): white solid (yield, 90%). 
1H NMR: (400 MHz, D2O): δ 4.99 (brs, 7 H, H-1 of -CD), 2.90 – 4.57 (m, 52 
H, H2-6 of -CD, -OCONHCH2-), 2.64 – 2.85 (m, 10 H, -CH2NH2). 
N-(2-aminoethyl)-2-aminoethyl-carbamoyl-β-cyclodextrin (β-CD-OEI-2): 
white solid. (yield, 82%) 1H NMR: (400 MHz, D2O): δ 4.99 (brs, 7 H, H-1 of 
β-CD), 2.87 – 4.57 (m, 54 H, H-2-6 of β-CD, -OCONHCH2-), 2.30 – 2.87 (m, 
38 H, -CH2CH2NH-). 
2-Aminoethyl-carbamoyl-γ-CD (γ-CD-OEI-1): white solid (yield, 84%). 
1H NMR: (400 MHz, D2O): δ 5.02 (brs, 8 H, H-1 of γ-CD), 2.87 – 4.55 (m, 64 
H, H2-6 of γ-CD, -OCONHCH2-), 2.69 (brs, 16 H, -CH2CH2N-). 
γ-CD-OEI-2/PTX: To a solution of γ-CD-OEI-2 (22 mg, 0.01 mmol) in 
H2O (0.5 mL) was added a solution of PTX (8.5 mg, 0.01 mmol) in ethanol 
(0.5 mL). The mixture was stirred at room temperature for 5 days under dark, 
and then centrifuged to remove the insoluble PTX. After evaporating the 
solvent to around 0.5 mL under vacuum by a rotary evaporator, the residue 
was centrifuged again to remove the precipitate and freeze dried for 2 d at –87 
ºC and 0.25 mbar to yield 25 mg of white solid (yield, 94%). 1H NMR: (400 
MHz, D2O): δ 7.20 – 8.15 (m, 9 H, ArH of PTX), 4.85 – 5.65 (m, 12 H, H-1 of 
γ-CD, H of PTX), 3.05 – 4.50 (m, 65 H, H2-6 of γ-CD, -CONHCH2- of OEI, 
H of PTX), 2.42 – 3.05 (s, 40 H, -CH2CH2NH- of OEI), 1.20 – 2.40 (m, 9 H, 
H of PTX). 
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α-CD-OEI-1/PTX, white solid (yield, 97%). 1H NMR: (400 MHz, D2O): δ 
7.20 – 8.13 (m, 0.7 H, ArH of PTX), 4.86 – 5.42 (m, 7.5 H, H-1 of α-CD, H of 
PTX), 2.98 – 4.53 (m, 48 H, H2-6 of α-CD, -CONHCH2- of OEI, H of PTX), 
2.56 – 2.98 (s, 10.4 H, -CH2CH2NH- of OEI), 1.12 – 2.40 (m, 1 H, H of PTX). 
α-CD-OEI-2/PTX, white solid (yield, 95%). 1H NMR: (400 MHz, D2O): δ 
7.15 – 8.11 (m, 1.4 H, ArH of PTX), 4.82 – 5.64 (m, 8.6 H, H-1 of α-CD, H of 
PTX), 2.98 – 4.55 (m, 52 H, H2-6 of α-CD, -CONHCH2- of OEI, H of PTX), 
2.40 – 2.98 (s, 31 H, -CH2CH2NH- of OEI), 1.12 – 2.40 (m, 2.5 H, H of PTX). 
β-CD-OEI-1/PTX, white solid (yield, 97%). 1H NMR: (400 MHz, D2O): δ 
7.19 – 8.15 (m, 4.9 H, ArH of PTX), 4.81 – 5.68 (m, 11 H, H-1 of β-CD, H of 
PTX), 2.97 – 4.52 (m, 56 H, H2-6 of β-CD, -CONHCH2- of OEI, H of PTX), 
2.66 – 2.97 (s, 10 H, -CH2CH2NH- of OEI), 1.12 – 2.40 (m, 4 H, H of PTX). 
β-CD-OEI-2/PTX, white solid. (yield, 94%) 1H NMR: (400 MHz, D2O): δ 
7.20 – 8.15 (m, 7 H, ArH of PTX), 4.83 – 5.68 (m, 12 H, H-1 of β-CD, H of 
PTX), 2.92 – 4.52 (m, 58 H, H2-6 of β-CD, -CONHCH2- of OEI, H of PTX), 
2.46 – 2.92 (s, 40 H, -CH2CH2NH- of OEI), 1.12 – 2.40 (m, 7 H, H of PTX). 
γ-CD-OEI-1/PTX, white solid (yield, 96%). 1H NMR: (400 MHz, D2O): δ 
7.20 – 8.20 (m, 5 H, ArH of PTX), 4.88 – 5.67 (m, 12 H, H-1 of γ-CD, H of 
PTX), 3.08 – 4.50 (m, 68 H, H2-6 of γ-CD, -CONHCH2- of OEI, H of PTX), 
2.40 – 3.07 (s, 16 H, -CH2CH2NH- of OEI), 1.20 – 2.40 (m, 6 H, H of PTX). 
Fluorescence Labeling: The general synthesis procedure of 
rhodamine-grafted γ-CD-OEI-2 (γ-CD-OEI-2-rhd) is as follows. To a solution 
of γ-CD-OEI-2 (22 mg, 10 μmol) in anhydrous DMSO (1 mL) was added 
rhodamine B (7 mg, 15 μmol), DCC (4 mg, 20 μmol), and DMAP (5%). The 
mixture was then stirred at room temperature for 1 day under dark. 
Purification by dialysis (MWCO, 1000) against water under dark for 5 days 
until no pink dye was observed. The mixture was freeze dried to yield a red 
solid as product. 
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PTX Labeling: The detailed synthetic method for PTX-FITC was 
followed previous report.35 The synthesized fluorescent PTX is bioactive and 
modification of 7-position will not influence the formation of inclusion 
complex with CD ring. 
3.2.3. NMR Spectroscopy. 
The 1H and 13C NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400.1 and 100.6 MHz at room temperature, respectively. The 
1H NMR measurements were carried out with an acquisition time of 3.2 s, a 
pulse repetition time of 2.0 s, a 30 pulse width, 5208 Hz spectral width, and 
32 K data points. Chemical shifts were referenced to the solvent peak ( = 
4.70 ppm for D2O,  = 2.50 ppm for DMSO-d6). 
The encapsulated PTX in the inclusion complex was calculated by 1H 
NMR by comparing the integration of PTX aromatic signal and OEI ethylene 
peaks. The PTX loading efficiency was calculated using the following 
equation: 
       (1) 
3.2.4. UV-Vis Spectroscopy 
All absorption spectra were recorded on a Shimadzu UV 2501 
spectrophotometer. 1 mL of aqueous solution containing α-, β-, γ-CD-OEI-2 
and α-, β-, γ-CD-OEI-2/PTX on a concentration of 0.2 mg/mL were 
transferred into quartz cuvettes for the measurement. 
3.2.5. Fourier Transform Infrared Spectroscopy 
Fourier transform infrared (FTIR) spectra of the γ-CD-OEI-2, PTX, and 
γ-CD-OEI-2/PTX inclusion complex in potassium bromide (KBr) were 
measured on a Perkin-Elmer FTIR 2000 spectrometer in the region of 4000 – 
400 cm-1. 
PTX loading efficiency = 
Amount of PTX
Amount of PTX + Polymer
× 100%
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3.2.6. Solubility Test 
The general procedure for solubility test is as follows. To a 100 μL of DI 
water was added the CD-OEI polymer or CD-OEI/PTX inclusion complex to 
prepare over-saturated solution. The mixture was centrifuged to precipitate the 
insoluble solid. Then 50 μL of supernatant was extracted, freeze dried, and the 
maximum solubility was calculated by weight. 
3.2.7. Stability Test 
The physical stability of CD-OEI/PTX inclusion complexes was evaluated 
as follows. A solution of 1 mL (3 mg/mL) CD-OEI/PTX inclusion complex 
was distributed into sealed glass tube and incubated at 25 ºC. At suitable 
intervals, 100 μL of solution was extracted and diluted into 1 mL solution with 
DI water. The absorptions of CD-OEI/PTX were measured by UV 
spectroscopy at 230 nm. 
In order to determine the concentrations of CD-OEI/PTX, a linear 
correlation of concentration – absorbance standard curve was drawn by 
measuring the absorption of β-CD-OEI-2/PTX (11.6% PTX according to 1H 
NMR) at 230 nm which the concentration changes from 0.01 to 0.8 mg/mL. 
Therefore, the concentrations of CD-OEI/PTX can be calculated according to 
the PTX absorbance at 230 nm and the drug loading efficiency obtained by 1H 
NMR and equation 1. 
3.2.8. Confocal Microscopy 
Confocal microscopy was used to evaluate the cellular uptake of 
PTX-7-FITC, γ-CD-OEI-2-rhd, and γ-CD-OEI-2-rhd/PTX-7-FITC in Hela 
cells. In brief, a density of 1.2 × 104/well Hela cells in 0.3 ml of DMEM 
medium were seeded onto a Lab-Tekfour-chambered coverglass system 
(Nalge-Nane International, Naperville, IL). After 24 h, fresh medium with 2 
μM of polymer was replaced. After incubation for 2 h, the medium was 
replaced with 0.3 mL of DMEM medium and imaged using an Olympus 
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Fluoview FV500 confocal laser scanning microscope (Olympus, Japan). Green 
fluorescence was excited by 488 nm laser line and detected using a 515 nm 
filter. The excitation wavelength for red fluorescence was set at 559 nm with 
an emission at 575 to 675 nm. 
3.2.9. Cell Viability Assay 
All cell lines were purchased from ATCC (Rockville, MD). Hela and 
MCF-7 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mg 
penicillin, 100 g/mL streptomycin at 37 C and 5% CO2. DMEM medium 
was purchased from Gibco BRL (Gaithersburg, MD). 
Hela and MCF-7 cells were cultured in DMEM medium supplemented 
with 10% FBS. 100 L of medium with a density of 1105 cells/mL were 
seeded into 96-well plates (NUNC, Wiesbaden, Germany). After 24 hours, 
culture media were replaced with fresh DMEM medium containing serial 
dilutions of polymers, in which the cells were cultured for an additional 20 
hours or 44 hours. Then 10 L of sterile filtered MTT (5 mg/mL) stock 
solution in PBS was added to each well, reaching a final MTT concentration 
of 0.5 mg/mL. After 4 h, unreacted dye was removed by aspiration. The 
formazan crystals were dissolved in 100 L/well DMSO and the absorbance 
was measured using a microplate reader (Spectra Plus, TECAN) at a 
wavelength of 570 nm. Four wells were treated together as a group. The 
relative cell growth (%) related to control cells cultured in media without 
polymer was calculated by [A]test/[A]control  100%. The IC50 value represents 
the concentration of polymer at which 50% reduction of cell growth was 
calculated. 
3.3. Results and Discussions 
The application of natural CDs usually limits by their low aqueous 
solubility and thus the formation of inclusion complexes with hydrophobic 
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molecules would be influenced, especially for β-CD. Generally, CD 
derivatives for pharmaceutical usage mainly include introduction of 
hydroxypropyl groups, methyl groups, and maltosyl groups. 
In our research, OEI chains with different lengths were linked into 
cyclodextrin rings, which illustrated significantly increase of water solubility 
and their capability to form inclusion complexes with anticancer drug PTX. 
3.3.1. Synthesis of CD-OEI/PTX Inclusion Complexes 
Scheme 3.1 shows the synthesis procedure of CD-OEI/PTX inclusion 
complexes. The 6-hydroxyl group from glucose units of CD exhibits high 
reactivity, which can be activated by CDI and then substituted by OEI with 
different ethylenediamine units to prepare OEI-grafted CD. Two methods 
were used to avoid the cross-linking between CDs. First, the CDI-activated 
intermediates were purified by precipitation under THF/Et2O. Second, slowly 
addition of CDI-modified CD derivatives into large excess of OEI solutions 
can reduce the cross-linking reaction. 
Table 3.1. Solubility of α-, β-, γ-CD-OEIs at 25 ºC 
 
* Solubility of α-, β-, γ-CD is 145, 18.5, and 232 mg/mL, respectively. 
PTX formed inclusion complexes with the CD-OEIs via physical 
interaction in a mixture of water/ethanol for several days under dark. Table 3.1 
illustrates the detailed structure and included PTX for each molecule. The 
Sample Glucose Units
NHCH2CH2-
repeat units OEI arms
Solubility Enhancement 
Factor*(mg/mL) (mM)
-CD-OEI-1 6 1 5.2 468 329 3 
-CD-OEI-2 6 2 5.2 586 356 4 
-CD-OEI-1 7 1 5.0 410 261 22 
-CD-OEI-2 7 2 6.3 460 235 25 
-CD-OEI-1 8 1 11.0 500 222 2 
-CD-OEI-2 8 2 7.0 580 263 3 
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encapsulation ability followed the order of α-CD<β-CD<γ-CD corresponding 
to their cavity size. Moreover, longer OEI chain and more substituted arms 
benefit to the formation of inclusion complex. 
 
Figure 3.2. 1H NMR spectra of PTX in CDCl3 (a), γ-CD-OEI-2 (b), and 
γ-CD-OEI-2/PTX (c) in D2O. 
As shown in Figure 3.2, 1H NMR provides direct evidence for the 
formation of inclusion complexes between γ-CD-OEI-2 and PTX. Generally, 
PTX has no signal in 1H NMR using D2O as solvent due to its extremely low 
water solubility. Therefore, the aryl signal in the spectra derived from PTX 
provided strong support for the formation of inclusion complex. The 
stoichiometry information can also be obtained according to integration 
between aryl area (δ 7.2 – 8.2 ppm) derived from PTX and ethylene signal (δ 
2.42 – 3.05 ppm) derived from γ-CD-OEI. Similarly, the number of included 
PTX with other CD-OEI carriers was also calculated according to their 1H 
NMR data. We found that even α-CD-OEI can help to solubilize PTX with 
satisfactory enhancement that is rarely reported, because the general opinion is 












Chapter 3. Cyclodextrins for Drug Delivery 
61 
 
Figure 3.3. 13C NMR spectra of PTX in CDCl3 (a), γ-CD (b), and 
γ-CD-OEI-2/PTX (c) in D2O. 
13C NMR spectrum of γ-CD-OEI-2/PTX was shown in Figure 3.3. The 
peak at δ 158.3 ppm is the urethane groups linked to the OEI chains, and the 
peaks at 37.5 – 50.0 ppm correspond to the OEI chains. Signals of γ-CD core 
can be found at chemical shift 102.5, 81.5, 73.5, 72.4, and 60.5. Furthermore, 
the peaks at δ 125.0 – 140.0 demonstrate the aromatic rings from PTX. The 
13C NMR data further proved the successful formation of inclusion complex. 
 
Figure 3.4. UV-Visible spectra of α-, β-, γ-CD-OEI-2 and α-, β-, 
γ-CD-OEI-2/PTX on a concentration of 0.2 mg/mL in H2O. The arrow indicates 
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UV-Vis spectroscopy was used to further confirm the formation of 
inclusion complexes. PTX aqueous solution also showed almost no absorption 
signal in UV-Vis spectroscopy because of its low solubility in water. In 
contrast, the inclusion complex of α-, β-, and γ-CD-OEI-2/PTX illustrated 
strong absorption at λ = 230 nm (Figure 3.4), indicating the typical signal of 
PTX. As shown in Figure 3.5, FT-IR spectroscopy illustrated that the C=O 
stretching vibration is shifted from 1732 cm-1 in PTX to 1704 cm-1 in the 
γ-CD-OEI-2/PTX inclusion complexes. The IR result is similar as previous 
reported data.33 
 
Figure 3.5. FT-IR spectra of γ-CD-OEI-2 (a), PTX (b), and γ-CD-OEI-2/PTX 
inclusion complex (c). 
3.3.2. Water Solubility and Stability 
β-CD has lower water solubility (18.5 g/L) than α-, and γ-CD (145 and 
232 g/L), which also influence the solubility of CD/drug inclusion complexes. 
As shown in Table 3.1, structure modification with OEIs significantly 
increased the water solubility of β-CD to more than 20 folds, and longer OEI 
chain will further increase the solubility. After conjugation with OEI arms 
with α-, and γ-CD, the solubility was increased as 2 – 4 folds. 
Table 3.2. Water solubility of CD-OEI/PTX inclusion complexes at 25 ºC 
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* The included PTX means number of PTX in one CD-OEI/PTX inclusion 
complex that is calculated by 1H NMR. 
Table 3.2 illustrated the enhanced solubility of PTX by CD-OEIs. The 
recommended administrated concentration of PTX is 0.7 – 1.4 mM.36 Our 
CD-OEI carriers can easily come up to the standard. α-CD-OEI-1 and 
α-CD-OEI-2 can also encapsulate up to 6 and 13 mM of PTX, respectively. In 
addition, the maximum PTX concentration in the formulation of 
β-CD-OEI-1/PTX and β-CD-OEI-2/PTX was 10 and 14 mM, respectively, 
which showed 24099-fold and 34430-fold higher than the pure PTX. Among 
of them, γ-CD-OEI-2 has the largest drug loading capacity that encapsulates 
51 mM PTX (123772-fold higher water solubility than pure PTX). In 
comparison, these synthesized CD-OEI derivatives illustrated significantly 
higher encapsulation of PTX than previous reported CD derivatives, such as 
random HP--CD (19-fold), DM--CD (120-fold), and so on.25 
A standard curve was drawn by determining the absorbance values of the 
difference concentrations of β-CD-OEI-2/PTX at 230 nm. It was calculated 
the following equation, where y is the absorbance values, and x is the 
concentration of β-CD-OEI-2/PTX. The calibration curve was linear under the 










PTX 3.5×10-4 - 4.1×10-4 - 1 .0 23
-CD-OEI-1/PTX 208 4.0×10-2 5.7 123 .3 1.4×104
-CD-OEI-2/PTX 220 0.1 12.7 126.9 3.1×104
-CD-OEI-1/PTX 86 0.2 9.9 49.4 2.4×104
-CD-OEI-2/PTX 104 0.3 14.1 47.1 3.4×104
-CD-OEI-1/PTX 220 0.3 26.3 87.6 6.4×104
-CD-OEI-2/PTX 230 0.6 50.7 84.6 1.2×105
HP--CD/PTX - 1.3×10-3 7.8×10-3 6.0 19.5 25
DM--CD/PTX - 8.2×10-3 4.9×10-2 6.0 1.2×102 25
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R2 = 0.0098. Moreover, the concentrations of CD-OEI/PTX can be calculated 
using equation 1 and 2. 
y = 3.2767x + 0.0085                                       (2) 
The stability test showed that the CD-OEI/PTX inclusion complexes were 
stable in aqueous solution. As displayed in Figure 3.6, after storage at 25 ºC 
from 2 h to 72 h, no PTX precipitate was observed in the tube for all the 
inclusion complexes and their PTX content had almost no change. 
 
Figure 3.6. Stability of α-, β-, γ-CD-OEI-1/PTX and α-, β-, γ-CD-OEI-2/PTX 
in aqueous solution with a concentration of 3 mg/mL from 2 to 72 hours at 25 
ºC. 
3.3.3. Cellular Uptake Test 
Figure 3.7 shows the cellular uptake of PTX-7-FITC, γ-CD-OEI-2-rhd, and 
γ-CD-OEI-2-rhd/PTX-7-FITC in Hela cells after treating polymers for 2 h. 
Directly administration of FITC-conjugated PTX showed relative low cellular 
uptake. In contrast, the red fluorescence stained γ-CD-OEI-2 showed very 
strong signals that illustrated very high cellular uptake, which renders these 
CD-OEIs to be potential drug delivery carriers. Moreover, green fluorescence 













- - I - - /PTX - - / X
- - / X  I-2/PTX- - EI-1/PTX
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with the inclusion complexes γ-CD-OEI-2-rhd/PTX-7-FITC for 2 h that 
indicated obvious drug release (Figure 3.7c, merged image). 
 
Figure 3.7. Confocal microscopy images of PTX-7-FITC (a), 
γ-CD-OEI-2-rhodamine (b), and γ-CD-OEI-2-rhodamine/PTX-7-FITC (c) in 
Hela cells. The same field of cells was observed by red fluorescent image (left), 
red and green merged image (middle), and bright field (right). 
3.3.4. Cell Viability Test 
The antitumor assay for the CD-OEI/PTX inclusion complexes was tested 
in vitro by the MTT assay using CD-OEI carriers and free PTX as reference 
compounds. As shown in Figure 3.8a and 3.8c, there is almost no cytotoxicity 
for all the CD-OEI derivatives when the concentration is 100 – 800 μg/mL in 
Hela and MCF-7 cells. Generally, γ-CD-OEI/PTX illustrated higher 
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same concentration due to their high drug loading efficiency (Figure 3.8b and 
3.8d). Although all the inclusion complexes illustrated PTX-induced 
cytotoxicity, their IC50 are still lower than the PTX in cremophor (IC50 = 5.1 
and 17.6 μg/mL in Hela and MCF-7 cells) in Hela and MCF-7 cells after 
treatment of 48 hours. 
 
 
Figure 3.8. Cell viability assay of α-CD-OEI-1, α-CD-OEI-2, β-CD-OEI-1, 
β-CD-OEI-2, -CD-OEI-1, -CD-OEI-2 in Hela (a) and MCF-7 cells (c), and 
α-CD-OEI-1/PTX, α-CD-OEI-2/PTX, β-CD-OEI-1/PTX, β-CD-OEI-2/PTX, 
-CD-OEI-1/PTX, -CD-OEI-2/PTX in Hela (b) and MCF-7 cells (d) at various 
concentrations for 48 hours in DMEM medium. Data represent mean  standard 
deviation (n = 4). 
3.4. Conclusions 
In this study, a series of short chain OEI grafted α-, β-, and γ-CDs were 
synthesized. The structures were confirmed by 1H NMR, 13C NMR, UV, and 
FT-IR spectroscopy. Modification of CD ring with OEI chains has 
significantly higher water solubility than the pure CD and higher 
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polymer can solubilize PTX up to 51 mM, which is much higher than most of 
the CD derivatives reported. Moreover, the CD-OEI/PTX inclusion complexes 
illustrated satisfactory stability in aqueous solution. Although the antitumor 
activity is lower than PTX/cremophor formulations, the absence of cremophor 
may expand their applications in clinical trials. Generally, the synthesized 
CD-OEI polymers are promising carriers for potentially drug delivery. 
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CHAPTER 4 FOLIC ACID MODIFIED CATIONIC 
-CYCLODEXTRIN-OLIGOETHYLENIMINE 
STAR POLYMER WITH BIOREDUCIBLE 
DISULFIDE LINKER FOR EFFICIENT 
TARGETED GENE DELIVERY 
4.1. Introduction 
In recent years, great interest has been focused on design and synthesis of 
safe and effective non-viral vectors to carry and protect oligonucleotides for 
gene therapy. Non-viral vectors, including cationic lipids, polymers, and 
dendrimers are promising due to their advantages over viral vectors, such as 
the safety, low cytotoxicity, easy manipulation, and ability to be readily 
functionalized.1 Polyethylenimine (PEI) is one of the most prominent 
examples of cationic polymers that have been extensively studied for non-viral 
gene delivery.2 The increase of gene delivery ability of PEI was observed as 
increasing of its molecular weight from 600 to 70,000 Da, but accompanied 
with high toxicity.3, 4 
Cyclodextrins (CDs) are a series of natural cyclic oligosaccharides 
composed of 6, 7, and 8 D(+)-glucose units linked by α-1,4-linkages, named 
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α-, β-, and γ-CD, respectively. These water-soluble, biocompatible 
oligosaccharides do not have immune responses and show low toxicity in 
animals and humans.5 CDs are usually used as solubilization and stabilization 
reagents for small molecules.6 Their application for oligonucleotide delivery 
thanks to the property that the hydroxyl groups of CD rings offer opportunity 
for multiple modifications. In 1999, Davis’ group reported the first synthesis 
of CD-conjugated cationic polymers for gene delivery.7 These CD-based 
polymers illustrated lower cytotoxicity and improved transfection efficiency as 
non-viral gene delivery vectors.8-10 Considering the good gene transfection 
efficiency of PEI, CD-modified PEI may have great potential as a promising 
gene delivery vector. Our group reported a series of cationic star polymers by 
conjugating PEI or oligoethylenimine (OEI) chains to α-CD as non-viral gene 
delivery vectors.11, 12 These CD-OEI star-shaped polymers showed much 
lower cytotoxicity and excellent gene transfection efficiency that were 
comparable to or even higher than that of the well-studied branched PEI (25 
kDa). 
The strategy to employ proper targeting groups is often used to develop 
gene delivery vectors which can target to specific cells or tissues. Folic acid 
(FA) is essential for the biosynthesis of nucleotide bases. Many malignant 
cells overexpress folate receptors (FRs) that is a high affinity folate-binding 
protein in cellular membrane,13 which renders FA an attractive candidate 
ligand for tumor-specific targeted gene delivery. Therefore, vectors conjugated 
with FA can be efficiently taken up by malignant cells which overexpress FRs 
via receptor-mediated endocytosis.14, 15 The total amount of folate-conjugated 
vectors internalized into a cell is roughly proportional to the overall number of 
FRs expressed on the cell.13 However, after the FRs on the cell surface are 
consumed during the internalization of the folate-conjugated vectors, the cells 
can no longer recognize the folate ligand, and the folate-conjugated vectors 
lose the ability of tumor-specific targeted delivery. Only if the cellular 
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membranes can readily recover the consumed FRs, the folate-conjugated 
vectors can be efficiently and continuously internalized by the target tumor 
cells.16 Therefore, the continuous recycling of FRs after cellular endocytosis is 
essential. 
Disulfide bond (-S-S-) is a covalent linkage which can be easily 
synthesized by oxidation of sulfhydryl, and can be cleaved in the presence of 
reducing agents. The oxidizing extracellular milieu and reducing intracellular 
space renders disulfide bond a delivery tool, which allows the vector to be 
degraded and to release the carried gene within the cells. In non-viral gene 
delivery systems, disulfide-based conjugates have been demonstrated to have 
higher gene transfection efficiency in comparison with disulfide-free 
precursors.17, 18 Low molecular weight PEI linked with reducible disulfide 
bond could assist uncoupling of PEI from DNA to enhance gene delivery, and 
the cleaved low molecular weight PEI could be easily cleared from the 
body.18-22 Disulfide bond was also incorporated in some folate-mediated 
targeted gene delivery systems, where disulfide linker was used to trigger 
cleavage of polymers followed by enhanced DNA release.23-25 Moreover, 
folate-drug conjugates with cleavable linkers (such as disulfide bond) were 
reported to ensure the release of drugs after endocytosis in the target cells.26-30  
Herein we design a folate-conjugated γ-CD-OEI star-shaped cationic 
polymer with disulfide bond as the linker between folate and γ-CD-OEI as a 
new multi-functional gene carrier. We have demonstrated that the newly 
designed γ-CD-OEI-SS-FA gene carrier had low cytotoxicity, and possessed 
capacity to target and deliver DNA to specific tumor cells that overexpress 
FRs, as well as function to recover and recycle FRs onto cellular membranes 
to facilitate continuous FR-mediated endocytosis to achieve very high levels 
of gene expression. 
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4.2. Experimental Section 
4.2.1. Materials 
Branched PEI (MW, 600 and 25,000), N,N'-dicyclohexylcarbodiimide 
(DCC), 4-dimehylaminopyridine (DMAP), folic acid (FA), buthionine 
sulphoximine (BSO), pyridine, and anhydrous dimethyl sulfoxide (DMSO) 
were purchased from Sigma-Aldrich. Cystamine dihydrochloride, succinic 
anhydride, 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazodium bromide 
(MTT), and DL-dithiothreitol (DTT) were obtained from Alfa Aesar (MA, 
U.S.A.). 1,1'-Carbonyldiimidazole (CDI), α-, β-, and γ-CD, were purchased 
from Tokyo Chemical Industry Co. Ltd (Tokyo, Japan). D2O and DMSO-d6 
used as solvents in the NMR measurement were obtained from Cambridge 
Isotope Laboratories, Inc. (Andover, U.S.A.). 
4.2.2. Synthesis Procedure 
The intermediates and the final cationic gene carriers were synthesized as 
follows. 
FA-SS-NH2: To a suspension of FA (265 mg, 0.6 mmol) and cystamine 
dihydrochloride (180 mg, 0.8 mmol) in a mixture of DMSO (4 mL) and 
pyridine (4 mL) was added DCC (144 mg, 0.7 mmol) and DMAP (cat.). The 
mixture was stirred at room temperature for 18 hours under dark, and then 
poured into acetone (80 mL). The yellow precipitate was collected and washed 
with acetone (40 mL) twice, and dried under vacuum to yield 330 mg of 
yellow solid (yield, 96%). The crude was used in the next step without further 
purification. 
FA-SS-COOH: To a solution of FA-SS-NH2 crude (330 mg, 0.6 mmol) in 
pyridine (5 mL) was added succinic anhydride (100 mg, 1.0 mmol), and then 
the mixture was stirred at room temperature for 18 hours under dark. The 
reaction mixture was then poured into acetone (80 mL). The yellow precipitate 
was collected, washed with acetone (40 mL) twice, and dried under vacuum to 
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yield 348 mg of yellow solid (yield, 90%). 1H NMR: (400 MHz, DMSO-d6): δ 
8.62 (s, 1 H, -CH- of pyrazine), 8.01 (brs, 2 H, -NH-), 7.63 (d, 2 H, J = 8.4 Hz, 
-CH- of benzyl ring), 6.90 (brs, 2H, -NH-), 6.62 (d, 2 H, J = 8.4 Hz, -CH- of 
phenyl ring), 4.47 (s, 2 H, -CH2-), 4.32 (m, 1 H, -CH-), 2.72 (t, 4 H, J = 6.8 
Hz, -CH2S-), 2.20 – 2.45 (m, 4 H, -CH2CO- of succinic anhydride), 1.80 – 
2.20 (m, 4 H, -CH2 of FA). 
γ-CD-OEI: To a solution of CDI (4.9 g, 30.0 mmol) in DMSO (30 mL) 
was added dropwise a solution of γ-CD (1.3 g, 1.0 mol) in DMSO (20 mL) 
during 1 h. After stirring for 20 h, the solution was added dropwise into a 
mixture of Et2O/THF (400 mL/200 mL). The white precipitate was collected 
by centrifuge and washed with Et2O/THF (20 mL/10 mL) twice, then 
dissolved into anhydrous DMSO (20 mL). The previous solution was added 
dropwise into a solution of PEI-600 (12.6 g, 21 mmol) in DMSO (40 mL) 
during 30 min, and then stirred at room temperature for an additional 24 h. 
Purification by dialysis (MWCO, 2000) against water for 5 d, freeze dried to 
yield 2.1 g of colorless solid (yield, 56.0%). 1H NMR: (400 MHz, D2O): δ 
5.05 (brs, 8 H, H-1 of γ-CD), 2.95 – 4.57 (m, 62 H, H-2-6 of γ-CD, 
-CONHCH2- of OEI), 1.87 – 2.95 (m, 395 H, -CH2CH2NH- of OEI). 
γ-CD-OEI-FA1.2: To a solution of γ-CD-OEI (110 mg, 20.9 μmol) and FA 
(9.2 mg, 20.8 μmol) in DMSO/Pyridine (1 mL/1 mL) was added DCC (4.3 
mg, 20.8 μmol) and DMAP (cat.). The mixture was stirred at room 
temperature for 18 hours under dark. Purification by dialysis (MWCO, 2000) 
against water under dark for 5 d, freeze dried to yield 95 mg of yellow solid 
(73.4%). 1H NMR: (400 MHz, D2O): δ 8.57 (s, 1.2 H, -CH- of pyrazine on 
FA), 7.65 (d, 2.4 H, -CH- of phenyl ring on FA), 6.77 (d, 2.4 H, -CH- of 
phenyl ring on FA), 4.98 (brs, 8 H, H-1 of γ-CD), 4.52 (2.4 H, -CH2NHPh- of 
FA), 4.25 (1.2 H, -CHCOOH- of FA), 3.00 – 4.50 (m, 63 H, H-2-6 of γ-CD, 
-CONHCH2- of OEI), 2.10 – 2.92 (m, 395 H, -CH2CH2NH- of OEI). 
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γ-CD-OEI-SS-FA0.8: To a solution of -CD-OEI (57 mg, 10 μmol) and 
FA-SS-COOH (7 mg, 10 μmol) in DMSO (1 mL) and pyridine (1 mL) was 
added DCC (2 mg, 10 μmol) and DMAP (cat.). The reaction mixture was 
stirred at room temperature for 18 hours under dark. Purification by dialysis 
(MWCO, 2000) against water under dark for 5 d, freeze dried to yield 42 mg 
of yellow solid (68%). 1H NMR (400 MHz, D2O): δ 8.45 – 8.61 (m, 0.8 H, 
-CH- of pyrazine on FA), 7.53 – 7.74 (m, 1.6 H, -CH- of phenyl ring on FA), 
6.57 – 6.81 (m, 1.6 H, -CH- of phenyl ring on FA), 5.02 (brs, 8 H, H-1 of 
γ-CD), 2.95 – 4.57 (m, 64 H, -CH2NHPh and -CHCOOH- of FA, H-2-6 of 
γ-CD, and -CONHCH2- of OEI), 1.88 – 2.95 (m, 395 H, -CH2CH2NH- of 
OEI). 
γ-CD-OEI-SS-FA1.3: To a solution of -CD-OEI (57 mg, 10 μmol) and 
FA-SS-COOH (10 mg, 15 μmol) in DMSO (1 mL) and pyridine (1 mL) was 
added DCC (3 mg, 15 μmol) and DMAP (cat.). The reaction mixture was 
stirred at room temperature for 18 hours under dark. Purification by dialysis 
(MWCO, 2000) against water under dark for 5 d, freeze dried to yield 54 mg 
of yellow solid (83%). 1H NMR (400 MHz, D2O): δ 8.42 – 8.69 (m, 1.3 H, 
-CH- of pyrazine on FA), 7.48 – 7.77 (m, 2.6 H, -CH- of phenyl ring on FA), 
6.54 – 6.84 (m, 2.6 H, -CH- of phenyl ring on FA), 5.00 (brs, 8 H, H-1 of 
γ-CD), 2.95 – 4.57 (m, 65 H, -CH2NHPh and -CHCOOH- of FA, H-2-6 of 
γ-CD, and -CONHCH2- of OEI), 1.91 – 2.96 (m, 395 H, -CH2CH2NH- of 
OEI). 
γ-CD-OEI-SS-FA1.7: To a solution of -CD-OEI (57 mg, 10 μmol) and 
FA-SS-COOH (16 mg, 25 μmol) in DMSO (1 mL) and pyridine (1 mL) was 
added DCC (5 mg, 25 μmol) and DMAP (cat.). The reaction mixture was 
stirred at room temperature for 18 hours under dark. Purification by dialysis 
(MWCO, 2000) against water under dark for 5 d, freeze dried to yield 57 mg 
of yellow solid (84%). 1H NMR (400 MHz, D2O): δ 8.42 – 8.70 (m, 1.7 H, 
-CH- of pyrazine on FA), 7.47 – 7.79 (m, 3.4 H, -CH- of phenyl ring on FA), 
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6.51 – 6.92 (m, 3.4 H, -CH- of phenyl ring on FA), 5.00 (brs, 8 H, H-1 of 
γ-CD), 2.98 – 4.57 (m, 66 H, -CH2NHPh and -CHCOOH- of FA, H-2-6 of 
γ-CD, and -CONHCH2- of OEI), 1.91 – 2.98 (m, 395 H, -CH2CH2NH- of 
OEI). 
4.2.3. Characterization Methods 
NMR Spectroscopy 
The 1H and 13C NMR spectra were recorded on a Bruker AV-400 NMR 
spectrometer at 400.1 and 100.6 MHz at room temperature, respectively. The 
1H NMR measurements were carried out with an acquisition time of 3.2 s, a 
pulse repetition time of 2.0 s, a 30 pulse width, 5208 Hz spectral width, and 
32 K data points. Chemical shifts were referenced to the solvent peak ( = 
4.70 ppm for D2O,  = 2.50 ppm for DMSO-d6). 
UV-Vis Spectroscopy 
All absorption spectra were recorded on a Shimadzu UV 2501 
spectrophotometer against a solvent blank. Absorption was measured in quartz 
cuvettes (frosted wall, 0.7 mL). Samples were dilute to 0.01 mg/mL for FA, 
and 0.1 mg/mL for cationic polymer γ-CD-OEI, γ-CD-OEI-FA1.2, and 
γ-CD-OEI-SS-FA1.3 before measurement. 
Release Test 
The concentrations of released FA by cleavage of disulfide linker from 
γ-CD-OEI-SS-FA using DTT were measured by UV-Vis spectroscopy. In 
Brief, 1.0 mL of γ-CD-OEI-SS-FA1.3 (5 mg/mL with DTT concentrations at 0 
μM, 10 μM, and 10 mM in PBS buffer) was loaded into dialysis tubes 
(MWCO 2000, Spectrum Laboratories Inc., USA). These dialysis tubes were 
put into centrifuge tubes immersed 50 mL of PBS solution with corresponding 
DTT concentrations. Then the centrifuge tubes were placed in a shaker 
agitated at 200 rpm and maintained the temperature at 37 ºC. At appropriate 
intervals, 1 mL of the dissolution medium was withdrawn and analyzed by 
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UV-Vis spectroscopy (Shimadzu UV 2501) at wavelength of 284 nm. 
Meanwhile, 1 mL of fresh medium was added to replace the medium that was 
withdrawn. 
Dynamic Light Scattering and Zeta-potential Measurements 
Particle size and zeta potential of the polymer/pDNA complexes were 
assessed using a Zetasizer Nano ZS (Malvern Instruments, Southborough, MA, 
USA) with a laser light wavelength of 633 nm at a 173 scattering angle. 
Briefly, 100 L of appropriate polymers mixed with 3 g of pDNA to prepare 
various solutions with N/P ratios ranging from 10 to 100. The mixture was 
vortexed for 30 s and incubated for 30 min at room temperature, and then 
diluted into 1 mL of distilled water and vortexed for 30 s before test by the 
Zetasizer. The particle size measurement was carried out at 25 C in triplicate.  
The deconvolution of the measured correlation curve to an intensity size 
distribution was accomplished using a nonnegative least squares algorithm. 
The Z-average hydrodynamic diameters of the particles were provided by the 
instrument. The Z-average size is the intensity weighted mean diameter 
derived from a Cumulants or single-exponential fit of the intensity 
autocorrelation function. The zeta potential measurements were carried using a 
capillary zeta potential cell in automatic mode with same samples measured 
for particle size. 
4.2.4. Biological Characterization Methods 
Plasmids 
The pRL-CMV (Promega, USA) plasmid, encoding Renilla luciferase, 
originally cloned from the marine organism Renilla reniformis was used. This 
plasmid DNA (pDNA) was amplified in Escherichia coli and purified 
following the protocol of supplier (Qiagen, Hilden, Germany). The 
concentration of the purified plasmid DNA was measured by optical density at 
260 and 280 nm. The quality was detected by electrophoresis in 1% agarose 
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gel. The purified pDNA was resuspended in TE buffer (10 mM Tris-Cl, pH 
7.5, 1 mM EDTA) and kept at a concentration of 1.0 mg/mL. 
Cells and Media 
All cell lines were purchased from ATCC (Rockville, MD). KB cells are 
FR-positive human nasopharyngeal cells, cultured in Minimum Essential 
Medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 0.3 g/L of L-glutamine, 0.1 g/L of sodium pyruvate, 100 units/mg of 
penicillin, and 100 g/mL of streptomycin at 37 C and 5% CO2. The A549 
human lung epithelial carcinoma cell line was cultured in Ham's F-12 Nutrient 
Mixture (F-12) supplemented with 10% FBS, 100 units/mg of penicillin, and 
100 g/mL of streptomycin at 37 C and 5% CO2. Roswell Park Memorial 
Institute (RPMI) 1640 medium (FA free) supplemented with 10% FBS, 100 
units/mg of penicillin, and 100 g/mL of streptomycin was used during cell 
viability and gene transfection test. MEM, F-12, and RPMI-1640 medium was 
purchased from Gibco BRL (Gaithersburg, MD). 
Gel Retardation Assay 
The binding ability of the all cationic polymers with pRL-CMV was 
tested by gel electrophoresis experiments. The sample solutions were diluted 
as various nitrogen concentrations by distilled water. Then pRL-CMV (0.1 
mg/mL of TE buffer) was mixed with an equal volume of previous polymer 
solution to prepare DNA/polymer complex at various nitrogen/phosphate 
(N/P) ratio solutions from 0 to 4. Each sample was vortexed and incubated for 
30 min at room temperature before loading to 1% agarose gel containing 0.5 
μg/mL ethidium bromide (EtBr). Gel electrophoresis was done in TAE buffer 
(40 mM Tris-acetate, 1 mM EDTA) at 100 V for 40 min in a Sub-Cell system 
(Bio-Rad Laboratories, CA). DNA bands were visualized by a UV lamp by a 
GelDoc system (Synoptics Ltd., UK). 
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Cell Viability Assay 
Human KB carcinoma cell line was cultured in FA free RPMI 1640 
medium supplemented with 10% FBS at 37 C, 5% CO2, and 95% relative 
humidity. 100 L of medium with a density of 1.5105 cells/mL were seeded 
into 96-well plates (NUNC, Wiesbaden, Germany). After 24 h, culture media 
were replaced with fresh culture media containing serial dilutions of polymers, 
in which the cells were cultured for 20 h. Then 10 L of sterile filtered MTT 
(5 mg/mL) stock solution in PBS was added to each well, reaching a final 
MTT concentration of 0.5 mg/mL. After 4 h, unreacted dye was discarded by 
aspiration. The formazan crystals were dissolved in 100 L/well DMSO and 
the absorbance was measured using a microplate reader (Spectra Plus, 
TECAN) at a wavelength of 570 nm. Five wells were treated together as a 
group. The relative cell growth (%) related to control cells cultured in media 
without polymer was calculated by [A]test/[A]control  100%. 
In vitro Transfection and Luciferase Assay 
Gene transfection efficiency studies were carried out in KB and A549 cell 
lines using pRL-CMV as reporter gene. In brief, 24-well plates were seeded 
with cells at a density of 8  104/well (KB cells) or 6  104/well (A549 cells) 
for 24 hours before transfection. The sample/DNA complexes at various N/P 
ratios were prepared by adding the samples into DNA solutions, followed by 
vortexing for 20 s and incubation for 30 min at room temperature before the 
transfection. Each well was first replaced with 400 μL of fresh RPMI 1640 
medium (FA free) for gene transfection efficiency test, or RPMI 1640 medium 
with FA at different concentrations (0.000, 0.001, 0.010, and 0.100 g/L) for 
FA competition test, or RPMI 1640 medium (FA free) with BSO at different 
concentrations (0, 50, 250, and 500 μM) for disulfide inhibition assay. Then 
the sample/DNA complexes were added into previous medium and incubated 
for 4 hours under standard incubator conditions. After 4 h, the medium was 
replaced with 500 μL of fresh RPMI 1640 medium (FA free), and the cells 
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were further incubated for an additional 20 hours under the same conditions. 
Cells were washed with PBS twice and added 100 L of cell culture lysis 
reagent (Promega, Cergy Pontoise, France), then shook at 1000 rpm for 2 
hours at room temperature before test. Luciferase gene expression was 
quantified using a commercial kit (Promega, Cergy Pontoise, France) and a 
luminometer (Berthold Lumat LB 9507, Germany). Protein concentration in 
the samples was analyzed using a bicinchoninic acid assay (Biorad, CA, 
USA). Absorption was measured on a microplate reader (Spectra Plus, 
TECAN) at 570 nm and compared to a standard curve calibrated with BSA 
samples of known concentration. Results are expressed as relative light units 
per milligram of cell protein lysate (RLU/mg protein). 
Confocal Microscopy 
Confocal microscopy was used to evaluate the expression of the plasmid 
pEGFP-N1 (Clontech Laboratories, Inc., Mountain View, CA), encoding a 
red-shifted variant of wild-type green fluorescence protein (GFP) by a KB cell 
line. In brief, a density of 1.2 × 104/well KB cells in 0.3 ml of RPMI 1640 
medium (FA free) were seeded onto a Lab-Tekfour-chambered coverglass 
system (Nalge-Nane International, Naperville, IL). After 24 h, EGFP 
polyplexes with PEI (25 kDa) at N/P ratio of 10, and the EGFP polyplexes 
with -CD-OEI, -CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3 at N/P ratio of 50 
were added into the transfection medium. After incubation for 4 h, the medium 
was replaced with 0.3 mL of fresh RPMI 1640 medium (FA free) and further 
incubated for an additional 20 hours under same conditions. The cells were 
imaged using an Olympus Fluoview FV500 confocal laser scanning 
microscope (Olympus, Japan). EGFP fluorescence was excited by 488 nm 
laser line and detected using a 515 nm filter. 
Statistical Analysis 
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Statistical analysis was carried out by a standard Student's t-test with a 
minimum confidence level of 0.05 as significant statistical difference. All the 
data are reported as mean ± standard deviation. 
4.3. Results and Discussion 
4.3.1. Synthesis of γ-CD-OEI-SS-FA 
γ-CD has 8 primary hydroxyl groups that can be easily modified. Scheme 
1 shows the synthesis procedures of FA-SS-COOH and γ-CD-OEI-SS-FA. 
γ-CD-OEI-FA was also synthesized as a control compound. Firstly, coupling 
reaction between FA and cystamine dihydrochloride was carried out by DCC 
and DMAP to introduce disulfide bond. Secondly, the amino-terminated FA 
was allowed to react with succinic anhydride to give FA-SS-COOH. The 
feeding ratio of DCC and cystamine was less than 1:1 to make sure that only 
the γ-carboxyl group of FA was conjugated with disulfide bond because 
over-modification of α-carboxyl group of FA may result in loss of binding 
ability to FR. Thirdly, the primary hydroxyl groups of γ-CD were activated by 
CDI, and then allowed to react with large excess of PEI-600 to give a 
γ-CD-OEI star-shaped cationic polymer (this step is similar to our previous 
report on the synthesis of cationic star-shaped α-CD-OEI polymers).11 To 
ensure there was no intra- or intermolecular crosslinking, the CDI-activated 
intermediate was purified by precipitation in Et2O/THF and large excess of 
PEI was used. Finally, unmodified FA and the FA-SS-COOH were allowed to 
react with γ-CD-OEI to produce γ-CD-OEI-FA and γ-CD-OEI-SS-FA, 
respectively. By varying the feeding ratio of FA-SS-COOH to γ-CD-OEI, 
three samples of γ-CD-OEI-SS-FA were obtained with different amounts of 
FA grafted onto γ-CD-OEI (Scheme 4.1b). 
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Scheme 4.1. Synthesis of FA with disulfide linker FA-SS-COOH (a) and 
γ-CD-OEI-FA and γ-CD-OEI-SS-FA (b). 
The successful synthesis of these samples was confirmed by 1H NMR, 13C 
NMR and UV-Vis spectroscopy. Figure 4.1 shows the 1H NMR spectra 
ofγ-CD-OEI-SS-FA0.8, γ-CD-OEI-SS-FA1.3, γ-CD-OEI-SS-FA1.7 in 
comparison with γ-CD-OEI and γ-CD-OEI-FA1.2. The typical signals from 
H-1 of γ-CD and OEI ethylene protons appeared at 5.0 and 1.9 – 3.0 ppm, 
respectively. The numbers of grafted OEI arms were calculated based on the 
integral ratios of these peaks. Successful linkage of FA to γ-CD-OEI was 
confirmed by their aromatic proton signals with chemical shifts at 6.8, 7.7, and 
8.6 ppm. Meanwhile, the number of grafted FA was determined to be 1.2 for 
γ-CD-OEI-FA1.2, 0.8 for γ-CD-OEI-SS-FA0.8, 1.3 for γ-CD-OEI-SS-FA1.3, and 
1.7 for γ-CD-OEI-SS-FA1.7 according to the peak integrals of FA aromatic 
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Figure 4.1. 1H NMR spectra of -CD-OEI (a), -CD-OEI-FA1.2 (b), 
-CD-OEI-SS-FA0.8 (c), -CD-OEI-SS-FA1.3 (d), and -CD-OEI-SS-FA1.7 (e) in 
D2O. 
13C NMR spectrum of γ-CD-OEI-SS-FA1.3 was shown in Figure 4.2. The 
peak at δ 158.0 ppm is the urethane groups linked to the OEI chains. In 
addition, the other carbonyl groups from FA can also be found at δ 160 – 180. 
Signals at chemical shift 101.7, 69.7, and 64.1 correspond to the β-CD core. 
Moreover, the peaks at δ 32.9 and 24.9 demonstrate the methylene groups 
derived from disulfide linker. The typical aromatic signals of FA were 
observed at δ 112.7, 128.8, 129.8, 147.8, and 151.8. The 13C NMR spectrum 
further demonstrates the successful conjugation of FA with disulfide linker. 
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Figure 4.2. 13C NMR spectra of -CD-OEI-SS-FA1.3 in D2O. 
UV-Vis spectroscopy was used to further confirm the structure of the 
synthesized γ-CD-OEI-FA and γ-CD-OEI-SS-FA. As shown in Figure 4.3, 
both γ-CD-OEI-FA1.2 and γ-CD-OEI-SS-FA1.3 have three absorption peaks at 
260, 291, and 369 nm, due to the conjugation of FA, while FA shows peaks at 
282 nm, and 362 nm. In contrast, γ-CD-OEI has no UV-Vis absorption. The 
positively charged γ-CD-OEI withdraws electrons of unsaturated aryl rings, 
causing red shifts of FA absorption bands from 282 nm to 291 nm, and 362 
nm to 369 nm. 
 
Figure 4.3. UV-Visible spectra of FA (0.01 mg/mL), γ-CD-OEI (0.1 mg/mL), 
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FA release test was used to demonstrate the cleavage of disulfide bond in 
the presence of DTT. γ-CD-OEI-SS-FA1.3 was incubated with 10 μM and 10 
mM of DTT in PBS at 37 ºC to mimic the different extracellular and 
intracellular environments, where glutathione (GSH) concentrations should be 
ca. 10 μM and ca. 1 – 10 mM, respectively. As shown in Figure 4.4, the 
degradation of disulfide bond was very slow at low DTT concentrations (0 and 
10 μM) and only 10% of FA derived from γ-CD-OEI-SS-FA1.3 was detected 
after 120 h. However, increasing DTT concentration to 10 mM significantly 
increased the reduction and cleavage rate of the disulfide bond in 
γ-CD-OEI-SS-FA1.3. As the result, more than 80% of FA released within 48 
hours, and nearly 100% of FA released at 120 hours. 
 
Figure 4.4. Release profiles of -CD-OEI-SS-FA1.3 in the absence and presence 
of DTT at 10 μM and 10 mM in PBS buffer (pH 7.4, 1.0 mL) at 37 ºC. 
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Figure 4.5. Electrophoretic mobility of pDNA in the polyplexes formed with 
PEI (a), -CD-OEI (b), -CD-OEI-FA1.2 (c), and -CD-OEI-SS-FA1.3 (d). The 
arrows indicate the N/P ratios where the DNA mobility is completely retarded. 
It is a prerequisite for a gene delivery vector to effectively condense DNA 
to form nanoparticles. When negatively charged DNA encounters positively 
charged cationic polymer in an aqueous solution, the electrostatic interaction 
will cause the phase separation of DNA and the polymer, which induces the 
formation of condensed DNA/polymer complexes (polyplexes) as colloidal 
nanoparticles suitable for cellular internalization through endocytosis and/or 
other pathways. The ability of cationic γ-CD-OEI-SS-FA1.3 to condense 
pDNA was analyzed by agarose gel electrophoresis in comparison with PEI 
(25 kDa), γ-CD-OEI, and γ-CD-OEI- FA1.2 (Figure 4.5). All the cationic 
polymers could entirely compact pDNA at N/P ratios of 2.5, which is same as 
the standard PEI. 
 
Figure 4.6. Particle size (a) and zeta potential (b) of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3, 
respectively, at various N/P ratios. 
The surface charge and particle size of the OEI-grafted polymers are 
important parameters for their biological application, which might be related 
to their blood circulation, cell encapsulation mechanism, and bioavailability.31, 
32 Figure 4.6 displays the results of zeta potential and particle size 
measurements of the pDNA complexes with PEI, γ-CD-OEI, γ-CD-OEI-FA1.2, 
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three cationic polymers efficiently compact pDNA into small nanoparticles 
with particle sizes around 100 – 150 nm, which is suitable for cellular uptake 
through endocytosis for gene delivery application.1 The surface charge of 
these complexes is around 20 – 40 mV in Figure 4.6b. Unlike the negative 
DNA, positive charged polymer/DNA complexes are easier to bind to cell 




Figure 4.7. Cell viability assay in KB cell line. The cells were treated with PEI 
(25 kDa), -CD-OEI, -CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3 at various 
concentrations for 24 hours in the absence (a) and presence (b) of FA (0.001 g/L) 
in RPMI 1640 medium. Data represent mean  standard deviation (n = 5). 
Cytotoxicity is an important factor that must be considered for gene 
delivery materials. Kissel et al. reported that the aggregation and adherence on 
the cell surface is the reason for the increased toxicity of PEI.33 Our previous 
studies showed that the introduction of CDs can reduce the toxicity of PEI or 
OEI.10, 11 Figure 6 shows the cell cytotoxicity of γ-CD-OEI, γ-CD-OEI-FA1.2, 
and γ-CD-OEI-SS-FA1.3 compared to PEI (25 kDa) in the absence (Figure 6a) 
and presence (Figure 6b) of FA in the culture medium. All the synthesized 
cationic polymers showed lower cytotoxicity than PEI (25 kDa). Since the 
cytotoxicity is mostly derived from the OEI chains, modification of γ-CD-OEI 
by FA and disulfide bond does not significantly change the cytotoxicity. In 
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disulfide linker resulted in slight decrease of cytotoxicity (Figure 6a and 6b). 
The addition of FA in the cell culture medium slightly decreased the 
cytotoxicity of all the samples (Figure 6b). The possible reason is that FA 
benefits cell growth of the control group (cells without polymers).34 
4.3.4. In vitro gene transfection 
 
Figure 4.8. In vitro gene transfection efficiency of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI-SS-FA0.8, -CD-OEI-SS-FA1.3, and 
-CD-OEI-SS-FA1.7 in KB cells in RPMI 1640 medium in the absence of FA. 
Data represent mean  standard deviation (*P < 0.05, n = 4). 
In vitro gene transfection efficiency was assessed using luciferase as a 
marker gene in FR-positive KB cells and FR-negative A549 cells. We first 
investigated the influence of the grafting amount of the targeting group FA on 
the gene delivery ability of γ-CD-OEI-SS-FA in FR-positive KB cells in 
RPMI 1640 medium (Figure 4.8). The RPMI 1640 medium does not contain 
free FA, so the FA ligand attached to γ-CD-OEI-SS-FA can facilitate the 
FR-mediated endocytosis. γ-CD-OEI-SS-FA1.3 showed the highest gene 
transfection ability among all three γ-CD-OEI-SS-FA samples, namely, 
γ-CD-OEI-SS-FA0.8, γ-CD-OEI-SS-FA1.3, and γ-CD-OEI-SS-FA1.7. The gene 
transfection efficiency of γ-CD-OEI-SS-FA1.3 was also higher than that of PEI 


























PEI γ-CD-OEI γ-CD-OEI-SS-FA-0.8 γ-CD-OEI-SS-FA-1.3 γ-CD-OEI-SS-FA-1.7
* * * ***
 - EI - -OEI- S-FA0. - -OEI- S-FA1. - -OEI- S-FA1.
 
Chapter 4. Cyclodextrins for Targeted Gene Delivery 
89 
γ-CD-OEI-SS-FA1.3 is considered optimized, and γ-CD-OEI-SS-FA1.3 was 
used in all the other experiments in this work.  
 
Figure 4.9. In vitro gene transfection efficiency of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3 in KB cells 
(a) and A549 cells (b) in RPMI 1640 medium in the absence of FA. Data 
represent mean  standard deviation (*P < 0.05, n = 4). 
Figure 4.9 shows the gene transfection efficiency of γ-CD-OEI-SS-FA1.3 
in KB and A549 cells in comparison with PEI (25 kDa), γ-CD-OEI, and 
γ-CD-OEI-FA1.2 in RPMI 1640 medium (without FA in the medium). In 
FR-positive KB cells (Figure 4.9a), the gene transfection efficiency constantly 
followed the order γ-CD-OEI-SS-FA1.3 > γ-CD-OEI-FA1.2 > γ-CD-OEI. The 
gene transfection efficiency of γ-CD-OEI-SS-FA1.3 was also constantly higher 
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significantly increased the gene transfection efficiency due to the FR-mediated 
cellular uptake. When comparing γ-CD-OEI-SS-FA1.3 and γ-CD-OEI-FA1.2, 
the only difference is that the former had disulfide link between FA and 
γ-CD-OEI, and the disulfide link could be cleaved by GSH within the cells 
and then FA could be released (Figure 4.4). Therefore, γ-CD-OEI-SS-FA1.3 
could not only efficiently deliver pDNA into FR-positive cells through 
FR-mediated cellular uptake, but also cleave FA from the carrier to release FR 
within the cells, and then recover FR onto cellular membrane to promote 
continuous FR-mediated cellular uptake of pDNA carried by 
γ-CD-OEI-SS-FA1.3. This is the reason that the transfection efficiency of 
γ-CD-OEI-SS-FA1.3 was constantly higher than that of γ-CD-OEI-FA1.2. At 
N/P ratio of 20 to 60, in general, the gene transfection efficiency of 
γ-CD-OEI-FA1.2 was 1 to 2 folds higher than that of γ-CD-OEI, while 
γ-CD-OEI-SS-FA1.3 was 2 to 4 folds higher than that of γ-CD-OEI, indicating 
that the significant improvement of the gene delivery efficiency was caused by 
the FA-conjugation as well as the incorporation of the disulfide bond. 
However, in FR-negative A549 cells (Figure 4.9b), FR-mediated cellular 
uptake was impossible, and the FA-conjugation showed no positive effect on 
the gene transfection efficiency. Inversely, the gene transfection efficiency 
constantly followed the order γ-CD-OEI > γ-CD-OEI-FA1.2 > 
γ-CD-OEI-SS-FA1.3, probably due to that the grafted FA interfered the normal 
endocytosis of the DNA polyplexes. 
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Figure 4.10. In vitro gene transfection efficiency of the pDNA polyplexes with 
-CD-OEI, -CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3 at N/P ratio of 50 in 
comparison with pDNA polyplexes with PEI (25 kDa) at N/P ratio of 10 in KB 
(a) and A549 (b) cells in RPMI 1640 medium treated with FA at different 
concentrations (0.000, 0.001, 0.010, and 0.100 g/L). Data represent mean  
standard deviation (*P < 0.05, n = 4). 
To further demonstrate the targeted effect of FA-grafted carriers, 
competition tests were carried out by addition of free FA at different 
concentrations (0.001, 0.010, and 0.100 g/L) to the cell culture medium during 
the gene transfection. As shown in Figure 4.10a, the gene transfection 
efficiency of both γ-CD-OEI-FA1.2 and γ-CD-OEI-SS-FA1.3 decreased with an 
increase in free FA concentration in FR-positive KB cells. In contrast, in 
Figure 4.10b, there were no significant changes in gene transfection efficiency 
for all carriers no matter whether there was FA-conjugation or not in 
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Figure 4.11. In vitro gene transfection efficiency of the pDNA polyplexes with 
PEI (25 kDa) at N/P ratio of 10 and pDNA polyplex with -CD-OEI, 
-CD-OEI-FA1.2, and -CD-OEI-SS-FA1.3 at N/P ratio of 50 in KB cells in 
RPMI 1640 medium treated with BSO at different concentrations (0, 50, 250, 
and 500 M). Data represent mean  standard deviation (*P < 0.05, n = 4). 
Sufficient FRs on the surface of cancer cells are a prerequisite for effect 
FR-mediated endocytosis.16 Therefore, the continuous recovering and 
recycling of FRs after cellular endocytosis is necessary for FA-targeted 
delivery. The biodegradable disulfide bond was used in our gene carrier to 
recover and recycle the FRs. Figure 4.11 demonstrates the results of the 
inhibitory test of disulfide bond using BSO, which can reduce the intracellular 
glutathione concentration,35, 36 resulting in inhibition of the cleavage of the 
disulfide bond. The transfection efficiency of γ-CD-OEI-SS-FA1.3 was 
significantly affected by the addition of BSO. It was 2-fold higher than that of 
γ-CD-OEI in the absence of BSO, but lower than that of γ-CD-OEI when BSO 
was used to inhibit the recovering and recycling of FRs in the FR-positive KB 
cells. The results further support our hypothesis that the disulfide bond plays 
an important role in this targeted delivery system. The FA-targeted delivery 
system with incorporation of disulfide bond is much superior to previous 
systems.11 
Finally, plasmid pEGFP-N1 encoding GFP was used to evaluate the GFP 
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fluorescence were observed for EGFP polyplexes with γ-CD-OEI-SS-FA1.3, 
which is significantly more than those of PEI (25 kDa), γ-CD-OEI, and 
γ-CD-OEI-FA1.2. This result further confirms that the gene delivery was 
enhanced by the FA-targeting moiety as well as the disulfide bond that links 
FA with the star-shaped cationic polymer. 
 
Figure 4.12. Confocal microscopy images of transfected KB cells by the EGFP 
polyplexes with PEI (25 kDa) (a), -CD-OEI (b), -CD-OEI-FA1.2 (C), and 
-CD-OEI-SS-FA1.3 (d) in RPMI 1640 medium in the absence of FA. N/P ratio 
was 10 for (a), and 50 for (b) – (d). For each experiment, the same field of cells 
was observed by fluorescent (left) and bright (right) fields to visualize GFP 
expression. 
4.4. Conclusions 
This work has designed and synthesized a new star-shaped cationic 
polymer containing a -cyclodextrin (-CD) core and multiple 
oligoethylenimine (OEI) arms with folic acid (FA) linked by a biodegradable 
disulfide bond for efficient targeted gene delivery. Three samples of the 
star-shaped cationic γ-CD-OEI-SS-FA polymers were prepared with ratios of 
FA to γ-CD-OEI of 0.8, 1.3, and 1.7. The γ-CD-OEI-SS-FA polymers could be 
cleaved efficiently and FA was readily released under reductive condition 
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characterized and studied in terms of its gene delivery properties in 
FR-positive KB cells and FR-negative A549 cells under various conditions, in 
comparison with cationic polymers such as PEI (25 kDa), γ-CD-OEI 
star-shaped cationic polymer, γ-CD-OEI-FA polymer where FA was directed 
linked to the star polymer without disulfide linker. The γ-CD-OEI-SS-FA 
polymers showed similar cytotoxicity to γ-CD-OEI and γ-CD-OEI-FA 
polymers, and much lower cytotoxicity than PEI (25kDa). The 
γ-CD-OEI-SS-FA polymers showed good DNA condensation ability and could 
retard pDNA at N/P ratio of 2.5, which is similar to all comparison cationic 
polymers used in this study. The γ-CD-OEI-SS-FA polymers formed DNA 
nanoparticles of sizes ranging from 100 to 150 nm with positive zeta potential 
ranging from 20 – 40 mV at N/P ratios of 10 to 60.  
It was found that γ-CD-OEI-SS-FA1.3 with the FA to γ-CD-OEI ratio of 
1.3 was the optimized composition for targeted gene delivery in FR-positive 
KB cells. The gene transfection efficiency of γ-CD-OEI-SS-FA1.3 was up to 6 
folds higher than that of PEI (25 kDa), 2 to 4 folds higher than that of 
γ-CD-OEI, and 2 folds higher than that of γ-CD-OEI-FA1.2 in FR-positive KB 
cells. The disulfide linker of γ-CD-OEI-SS-FA1.3 could be cleaved by GSH 
within the cells. Therefore, γ-CD-OEI-SS-FA1.3 could not only efficiently 
deliver pDNA into FR-positive cells through FR-mediated cellular uptake, but 
also cleave FA from the carrier to release FR within the cells, and then recover 
FR onto cellular membrane to promote continuous FR-mediated cellular 
uptake of pDNA, to achieve very high levels of gene expression. FA 
competition and disulfide inhibitory tests demonstrated that the significantly 
enhanced gene expression was induced by the targeted effect of FA and the 
FR recovery and recycling facilitated by disulfide linker in FR-positive KB 
cells. Moreover, in FR-negative A549 cells, all the effects due to 
FA-conjugation and disulfide bond were not observed. 
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This study has expanded the strategy of FA-targeted delivery by 
combining the smart FR-recycling function to achieve the significant 
enhancement of gene expression. The new FA-targeted and biodegradable 
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CHAPTER 5 A MULTIFUNCTIONAL 
SUPRAMOLECULAR SELF-ASSEMBLY 
FORMING A SYNERGISTIC TARGETED AND 
CO-DELIVERY SYSTEM OF GENE AND DRUG 
FOR POTENTIAL CANCER THERAPY 
5.1. Introduction 
Combination of two or more different therapeutic and delivery strategies 
with synergistic and enhancement effects is becoming a promising approach 
for cancer therapy.1-5 Paclitaxel (PTX) is one of the most commonly used 
chemotherapeutic drugs against ovarian, breast, head and neck, and 
non-small-cell lung cancers.6, 7 PTX binds to tubulin and promotes tubulin 
polymerization and stabilization of microtubules against depolymerization.8, 9 
As a result, PTX-induced microtubule stabilization leads to G2/M cell cycle 
arrest and cell death.10 One of the major problems for PTX application is its 
low aqueous solubility (0.3 μg/mL).11 On the other hand, chemotherapy is 
generally limited by the side effects and multidrug resistance. 
Gene therapy has obtained great attention over the past two decades as an 
alternative method to conventional chemotherapy.12, 13 Tumor suppressor 
 
Chapter 5. Cyclodextrins for Drug and Gene Co-delivery 
99 
protein gene, such as p53, is one of the most frequently delivered genes for 
effective cancer therapy. The p53 protein plays a role as a prevailing guardian 
in damaged or transformed cells, which induces cell growth arrest or 
apoptosis.14 Cells cannot control their growth if normal protective function of 
p53 is lost, resulting in rapid growth and progression toward malignancy.15, 16 
Moreover, mutant or loss of p53 gene has been found in around 50% of human 
cancers,17 and the loss of p53 may also result in resistance to radiotherapy or 
chemotherapy.18 Therefore, the reinstatement of wild-type p53 expression is a 
reasonable approach for cancer therapy. 
Co-delivery of DNA and anticancer drug, such as doxorubicin and PTX 
has shown great promise to achieve the synergistic or combined effects in 
cancer therapy.19-25 The co-delivery of paclitaxel and plasmid DNA by 
cationic core-shell nanoparticles improved gene transfection both in vitro and 
in vivo.21 The co-delivery of doxorubucin and p53 gene by micelles increased 
p53 mRNA expression level as well as cytotoxicity towards HepG2 cells.19 
The presence of PTX would enhance gene expression possibly due to its 
anti-mitotic function.26, 27 Although PTX-induced apoptosis is 
p53-independent,10, 28 the status of p53 may influence the cell-cycle 
progression following mitotic arrest.29, 30 Adenovirus-mediated p53 gene 
therapy with PTX had synergistic effect in many cancer cell lines.31 
Cyclodextrins (α-, β-, and γ-CD) are a series of natural cyclic 
oligosaccharides consisting of 6, 7, or 8 D(+)-glucose units, taking a torus-like 
structure with a hydrophobic cavity.32 These water-soluble molecules have 
low toxicity in animals and humans.33 CDs are potential candidates for drug 
delivery thanks to their ability to form inclusion complexes with guest 
molecules and consequently change their physical, chemical, and biological 
properties.34 Inclusion complexes between CD derivatives and PTX to 
improve the physical properties of PTX have been widely investigated in the 
last two decades.35-41 Davis’ group synthesized CD-based cationic polymers 
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for gene delivery.42-45 Our group also reported a series of CD-based cationic 
star-shape or supramolecular polymers by grafting oligoethylenimine (OEI) 
chains to CD rings as non-viral gene delivery vectors,46-49 which showed much 
lower cytotoxicity and improved gene transfection efficiency that were 
comparable to or even higher than that of high molecular weight branched PEI 
(25 kDa). We recently developed folic acid (FA) modified -CD-OEI with 
bioreducible disulfide linker (-CD-OEI-SS-FA) as an efficient gene delivery 
carrier.50 The new -CD-OEI-SS-FA carrier can specifically target and deliver 
DNA to cancer cells that overexpress folate receptors (FRs) due to the 
ligand-receptor interaction and the recycling of FRs onto cellular membranes 
to assist FR-mediated endocytosis induced by the reduction of disulfide linker 
within the cells. 
In this work, the γ-CD-OEI-SS-FA gene carrier has been developed into a 
multifunctional drug and gene co-delivery system through supramolecular 
self-assembly to form inclusion complexation between the γ-CD core and PTX 
followed by polyplexing plasmid DNA (pDNA) encoding luciferase or p53 
gene (Scheme 5.1). Our data have demonstrated that the multifunctional 
γ-CD-OEI-SS-FA/PTX self-assembly co-delivery system showed the 
combined and synergistic effects of the PTX-enhanced gene transfection, the 
FA-targeted delivery, and the disulfide linker mediated FR-recycling. The 
multifunctional synergistic effects resulted in very effective deliver of 
wild-type p53 gene into FR-overexpressed KB cancer cells at very low N/P 
ratios to induce an efficient cell apoptosis for potential cancer therapy. 
5.2. Experimental Section 
5.2.1. Materials 
Paclitaxel (PTX) was purchased from LC Laboratories (MA, USA). 
N,N'-dicyclohexylcarbodiimide (DCC), 4-dimehylaminopyridine (DMAP), 
rhodamine B (Rhd), fluorescein isothiocynate (FITC), buthionine 
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sulphoximine (BSO), and anhydrous dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich. 3-(4,5-Dimethyl-thiazol-2-yl)-2,5-diphenyl 
tetrazodium bromide (MTT) was obtained from Alfa Aesar (MA, USA). D2O 
and CDCl3 used as solvents in the NMR measurement were purchased from 
Cambridge Isotope Laboratories, Inc. (Andover, USA). γ-CD-OEI-SS-FA and 
its control compounds γ-CD-OEI and γ-CD-OEI-FA were synthesized 
according to our previous report.50  
5.2.2. Preparation of Inclusion Complexes 
The general synthesis procedure of inclusion complexes of 
γ-CD-OEI-SS-FA (or the control compounds) with PTX is as follows. To a 
solution of γ-CD-OEI-SS-FA (10 μmol) in water (1 mL) was added a solution 
of PTX (8.5 mg, 10 μmol) in ethanol (1 mL). The suspension was then stirred 
for five days in the dark until a clear solution formed. The mixture was 
concentrated under vacuum to a volume of c.a. 1 mL, centrifuged to remove 
unreacted PTX, and then freeze dried to yield the product.  
γ-CD-OEI/PTX inclusion complex was colorless solid (65 mg, yield 
99%). 1H NMR: (400 MHz, D2O): δ 7.22 – 8.13 (m, 15 H, ArH of PTX), 4.80 
– 5.65 (m, 12 H, H-1 of γ-CD, H of PTX), 2.87 – 4.55 (m, 69 H, H-2-6 of 
γ-CD, -CONHCH2- of OEI, H of PTX), 2.00 – 2.87 (m, 407 H, -CH2CH2NH- 
of OEI, H of PTX), 0.80 – 2.00 (m, 18 H, H of PTX). 
γ-CD-OEI-FA/PTX inclusion complex was yellow solid (68 mg, yield 
97%). 1H NMR: (400 MHz, D2O): δ 8.52 (s, 1.2 H, -CH- of pyrazine on FA), 
7.20 – 8.12 (m, 17.4 H, ArH of PTX, 2.4 H, -CH- of phenyl ring on FA), 6.69 
(d, 2.4 H, -CH- of phenyl ring on FA), 4.70 – 5.62 (m, 12 H, H-1 of γ-CD, H 
of PTX), 2.93 – 4.52 (m, 77 H, H-2-6 of γ-CD, -CONHCH2- of OEI, H of 
PTX), 2.00 – 2.93 (m, 407 H, -CH2CH2NH- of OEI, H of PTX), 0.80 – 2.00 
(m, 18 H, H of PTX). 
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γ-CD-OEI-SS-FA/PTX inclusion complex was yellow solid (72 mg, yield 
97%). 1H NMR: (400 MHz, D2O): δ 8.40 – 8.60 (m, 1.3 H, -CH- of pyrazine 
on FA), 7.20 – 8.12 (m, 17.6 H, ArH of PTX, 2.6 H, -CH- of phenyl ring on 
FA), 6.60 – 6.80 (m, 2.6 H, -CH- of phenyl ring on FA), 6.69 (d, 2.4 H, -CH- 
of phenyl ring on FA), 4.72 – 5.65 (m, 12 H, H-1 of γ-CD, H of PTX), 2.97 – 
4.52 (m, 77 H, H-2-6 of γ-CD, -CONHCH2- of OEI, H of PTX), 2.00 – 2.97 
(m, 407 H, -CH2CH2NH- of OEI, H of PTX), 0.80 – 2.00 (m, 18 H, H of 
PTX). 
Fluorescence Labeling: The general synthesis procedure of 
rhodamine-grafted γ-CD-OEI-SS-FA (or the control compounds) is as follows. 
To a solution of γ-CD-OEI derivatives (2 μmol) in anhydrous DMSO (1 mL) 
was added rhodamine B (1.4 mg, 3 μmol), DCC (0.8 mg, 4 μmol), and DMAP 
(0.05 mg, 0.4 μmol). The mixture was then stirred at room temperature for one 
day in the dark. Purification by dialysis (MWCO 2000) against water was 
conducted in the dark for five days. The mixture was freeze dried to yield red 
oil product. Three rhodamine-grafted carriers were synthesized, including 
γ-CD-OEI-Rhd, γ-CD-OEI-FA-Rhd, and γ-CD-OEI-SS-FA-Rhd. 
PTX Labeling: The synthesis method for PTX-FITC was adopted from 
previous report.51 According to the reference, the 7-substituted fluorescent 
PTX maintains its bioactivity. Moreover, the modification of 7-position will 
not influence the formation of inclusion complex with CD, since the A and B 
phenyl rings of PTX are the binding groups within the cavity of CD.37, 38 
5.2.3. Characterization Methods 
Gel Permeation Chromatography: Gel permeation chromatography 
(GPC) analysis was conducted on a Shimadzu SCL-10A and LC-10AT system 
equipped with a Sephadex G-75 column (size: 2.5 × 32 cm) and a Shimadzu 
RID-10A refractive index detector. PBS buffer solution (0.5 ×) was used as 
the eluent, and the fractions were collected per 2 mL and were further detected 
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with a HORIBA SEPA-300 high speed accurate polarimeter at wavelength 
589 nm with cell length 10 cm and response 2 s. 
1H NMR Spectroscopy: 1H NMR spectra were measured on a Bruker 
AV-400 NMR spectrometer at 400 MHz. The 1H NMR measurements were 
carried out with an acquisition time of 3.2 s, a pulse repetition time of 2.0 s, a 
30 pulse width, 5208 Hz spectral width, and 32 K data points. Chemical 
shifts were referenced to the solvent peak ( = 4.70 ppm for D2O). 
UV-vis Spectroscopy: All absorption spectra were recorded on a Shimadzu 
UV 2501 spectrophotometer against water blank. Absorption was measured in 
quartz cuvettes (frosted wall, 0.7 mL). All the samples were diluted to 0.1 
mg/mL of aqueous solutions. 
5.2.4. Biological Characterization Methods 
Plasmids: The plasmid pRL-CMV encoding a Renilla luciferase reporter 
gene was purchased from Promega (Madison, USA). The plasmid pCMV-p53 
(wild type) and pCMV-p53mt135 (dominant-negative) were purchased from 
Clontech Laboratories Inc. (Mountain View, USA). All these plasmids were 
amplified in Escherichia coli and purified according to the protocol of 
suppliers (Qiagen, Hilden, Germany). The concentrations of the purified 
plasmid DNA were measured by UV spectroscopy under optical density at 
260 and 280 nm. The quality was analyzed by gel electrophoresis. The 
plasmids were resuspended in TE buffer (10 mM Tris-Cl, pH 7.5, 1 mM 
EDTA) and kept at a concentration of 0.5 mg/mL for storage. 
Cells and Media: KB and A549 cell lines were purchased from ATCC 
(Rockville, MD). KB cells are FR-positive human nasopharyngeal cells, 
cultured in Minimum Essential Medium (MEM) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 0.3 g/L of L-glutamine, 0.1 g/L of 
sodium pyruvate, 100 units/mg of penicillin, and 100 g/mL of streptomycin. 
The A549 human lung epithelial carcinoma cell line was cultured in Ham's 
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F-12 Nutrient Mixture (F-12) supplemented with 10% FBS, 100 units/mg of 
penicillin, and 100 g/mL of streptomycin. Roswell Park Memorial Institute 
(RPMI) 1640 medium (FA free) supplemented with 10% FBS, 100 units/mg 
of penicillin, and 100 g/mL of streptomycin was used during cell viability 
and gene delivery test. All the cells were cultured in an incubator at 37 C 
with 5% CO2, and 95% relative humidity. MEM, F-12, and FA-free RPMI 
1640 medium were purchased from Gibco BRL (Invitrogen, Singapore). 
Gel Retardation Assay: Gel electrophoresis was used to assay the binding 
ability of all the synthesized polymers with plasmid pRL-CMV. Briefly, 5 μL 
of polymer solutions were added into 5 μL of plasmid solutions (0.1 mg/mL) 
to prepare various nitrogen/phosphate (N/P) ratio solutions from 0 to 4. The 
polyplexes were incubated for 30 min at room temperature, and then mixed 
with 1 μL of loading buffer (10×) before loading to 1% agarose gel containing 
0.5 μg/mL of ethidium bromide (EtBr). Gel electrophoresis was carried out in 
TAE buffer (40 mM Tris-acetate, 1 mM EDTA) at 100 V for 30 min in a 
Sub-Cell system (Bio-Rad Laboratories, CA). DNA bands were visualized by 
a UV lamp with MULTI GENIUS BioImaging System (Syngene, UK). 
Dynamic Light Scattering and Zeta-potential Measurements: Particle size 
and zeta potential of the polymer/pRL-CMV polyplexes were tested by a 
Zetasizer Nano ZS (Malvern Instruments, Southborough, USA) with a laser 
light wavelength of 633 nm at a 173 scattering angle. In general, 50 L of 
polymer solutions were added into 50 L of plasmid solutions (0.1 mg/mL) to 
prepare various solutions with N/P ratios ranging from 10 to 50. The mixtures 
were vortexed for 20 s and incubated at room temperature for 30 min. The 
polyplexes were diluted with 0.9 mL of distilled water and vortexed for 20 s 
before test. The particle size measurement was done at 25 C. The 
deconvolution of the measured correlation curve to an intensity size 
distribution was accomplished using a nonnegative least squares algorithm. 
The Z-average hydrodynamic diameters of the particles were provided by the 
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instrument. The Z-average size is the intensity weighted mean diameter 
derived from a Cumulants or single-exponential fit of the intensity 
autocorrelation function. The zeta potential measurement was tested using a 
capillary zeta potential cell in automatic mode. 
Cell Viability Assay: 100 L of FA-free RPMI 1640 medium with 1.5  
104 KB cells was seeded into 96-well plates (NUNC, Wiesbaden, Germany). 
After 24 h, the culture media were replaced with fresh media containing serial 
dilutions of polymers, and then the cells were cultured for an additional 20 h. 
Then, 10 L of sterile filtered MTT (5 mg/mL) stock solution in PBS was 
added to each well. After incubation for 4 h, the medium were removed by 
aspiration. The formazan crystals were dissolved in 100 L/well of DMSO. 
Then the absorbance was measured by a microplate reader (Spectra Plus, 
TECAN) at a wavelength of 570 nm. The relative cell growth (%) related to 
control cells without polymer was calculated by [A]test/[A]control  100%. 
In vitro Transfection and Luciferase Assay: Gene transfection efficiency 
was tested using pRL-CMV as reporter gene in KB and A549 cells. Cells with 
a density of 8  104/well (KB cells) or 6  104/well (A549 cells) were seeded 
into 24-well plates for 24 hours. 10 L of polymer solutions were added into 
10 L of plasmid solutions (0.1 mg/mL) to prepare various solutions with N/P 
ratios ranging from 10 to 50. The polyplexes were vortexed for 20 s and 
incubated for 30 min at room temperature before the transfection. Each well 
was first replaced with 400 μL of fresh FA-free RPMI 1640 medium, and then 
added 20 L of polymer/DNA polyplexes. After incubation for 4 hours, the 
medium was replaced with 500 μL of fresh FA-free RPMI 1640 medium, and 
the cells were further incubated for 20 hours under the same conditions. At the 
end of transfection, cells were washed with PBS twice and added 100 L of 
lysis reagent (Promega, Cergy Pontoise, France). The plates were shook at 
1000 rpm for 1 hour at room temperature before test. Luciferase gene 
expression was tested using a commercial kit (Promega, Cergy Pontoise, 
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France) by a luminometer (Berthold Centro LB 960, Germany). The Protein 
concentrations were measured by Commassie PlusTM Protein Assay Reagent 
(Pierce). Absorption was measured using a microplate reader (Spectra Plus, 
TECAN) at 595 nm and compared to a standard curve calibrated by BSA 
solutions. The results are expressed as relative light units per milligram of cell 
protein lysate (RLU/mg protein). 
FA Competition and BSO Inhibitory Test: FA competition and BSO 
inhibitory test were carried out to inhibit the FR-mediated endocytosis and 
disulfide linker-mediated FR recycling function. The transfection procedure is 
the same as previous described luciferase assay. RPMI 1640 medium with 
0.001 g/L of FA or 250 μM of BSO was used in these two experiments, 
respectively. The optimal N/P ratio of 15 was adopted at which the PTX 
inclusion complexes have the highest transfection efficiency. 
Cell Cycle Analysis: Two plasmids pCMV-p53 and mutant 
pCMV-p53mt135 were delivered into FR-positive KB cells and FR-negative 
A549 cells by the cationic polymers to assay the cell growth inhibition. The 
pCMV-p53 expresses the wild-type p53 tumor suppression protein while the 
pCMV-p53mt135 expresses a dominant-negative mutant. The procedure of 
transfection is the same as previously described. At the end of transfection, the 
cells were washed with PBS twice and added 300 μL of 1× trypsin. After 
incubation for 8 min, 500 μL of medium was added. The cells were collected 
by centrifuge at 2000 rpm for 5 min, washed with PBS, and fixed with 70% 
ethanol for 2 h at 4 ºC. After washing with PBS, the cells were suspended into 
PBS solutions with 0.2% Triton X-100, 20 μg/mL of propidium iodide, and 
0.2 mg/mL of RNase (BD Biosciences, San Diego, CA). The mixtures were 
incubated at 37 ºC for 20 min and stored at 4 ºC before test. The distribution of 
cells in the various phases of cell cycle (sub G1, G0/G1, S, and G2/M) was 
measured using flow cytometry (FACSCalibur, Becton Dickinson, NJ). 
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Confocal Microscopy: Confocal microscopy was conducted to assay the 
cellular uptake of pRL-CMV polyplexes with the rhodamine stained cationic 
polymers and their inclusion complexes with FITC stained PTX. In brief, a 
density of 1.5 × 104/well KB cells in 0.3 ml of FA-free RPMI 1640 medium 
were seeded onto a Lab-Tekfour-chambered coverglass system (Nalge-Nane 
International, Naperville, IL). After 24 h, the pRL-CMV polyplexes with 
-CD-OEI-Rhd, -CD-OEI-FA-Rhd, -CD-OEI-SS-FA-Rhd, and the inclusion 
complexes of -CD-OEI-Rhd/PTX-FITC, -CD-OEI-FA-Rhd/PTX-FITC, 
-CD-OEI-SS-FA-Rhd/PTX-FITC, and -CD-OEI-SS-FA/PTX-FITC at N/P 
ratio of 15 were added into the transfection medium. After incubation for 1 h, 
the medium was replaced with 0.3 mL of fresh medium and imaged using an 
Olympus Fluoview FV500 confocal laser scanning microscope (Olympus, 
Japan). The excitation wavelength was set at 488 nm for FITC and 559 nm for 
rhodamine. The optical filter for emission signal of FITC and rhodamine is 
515 nm and 575 to 675 nm, respectively. 
Statistical Analysis: Statistical analysis was performed by a standard 
Student's t-test with a minimum confidence level of 0.05 as significant 
statistical difference. All the data are reported as mean ± standard deviation. 
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5.3. Results and Discussion 
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Scheme 5.1. (a) Structures of γ-CD-OEI-SS-FA. (b) Schematic presentation of 
the supramolecular self-assembly process for formation of the 
γ-CD-OEI-SS-FA/PTX inclusion complex. (c) Illustration of the concept of the 
drug and gene co-delivery mediated by the multifunctional supramolecular 
self-assembly. 
The γ-CD-based gene carriers, including γ-CD-OEI, γ-CD-OEI-FA, and 
γ-CD-OEI-SS-FA were synthesized according to our previous reported 
procedures,50 and their structures are shown in Scheme 5.1. The γ-CD core of 
these gene carriers should be capable of forming inclusion complexes with 
hydrophobic drugs such as PTX. To synthesize the inclusion complexes of 
PTX with these γ-CD-based gene carriers, 1:1 ratio of γ-CD-based cationic 
polymers and PTX were dissolved in a mixture of water and ethanol (v:v = 
1:1) and stirred at room temperature for five days in the dark. As the PTX was 
gradually included into the hydrophobic cavity of the γ-CD ring, the reaction 
mixture turned from a suspension to a clear solution after rigorous stirring. 
The formation of clear solution was considered completion of the inclusion 
complexation, and the time required for the completion of complexation 
followed the order γ-CD-OEI < γ-CD-OEI-FA ≤ γ-CD-OEI-SS-FA due to the 
steric effects. 
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Figure 5.1. Size exclusion chromatography diagrams of γ-CD (a), γ-CD-OEI 
(b), γ-CD-OEI-SS-FA (c), and γ-CD-OEI-SS-FA/PTX (d) recorded with 
refractive index (RI) and optical rotation (OR). 
Figure 5.1 shows the size exclusion chromatography diagrams of 
γ-CD-OEI-SS-FA/PTX inclusion complex in comparison with 
γ-CD-OEI-SS-FA, γ-CD-OEI, and γ-CD. Free γ-CD (MW 1297) has small 
molecular size, whose peak was observed at the low molecular weight range 
of the diagram. The peaks of γ-CD-OEI, γ-CD-OEI-SS-FA, and 
γ-CD-OEI-SS-FA/PTX complex were observed at high molecular weight 
range, showing similar elution times due to the similar molecular weights 
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Figure 5.2. 1H NMR spectra of γ-CD-OEI (a), γ-CD-OEI/PTX (b), 
γ-CD-OEI-FA/PTX (c), γ-CD-OEI-SS-FA (d), and γ-CD-OEI-SS-FA/PTX (e) 
in D2O. 
PTX has very poor water solubility,11 which gives no signals in 1H NMR 
and UV-vis spectroscopy when D2O and water were used as solvent, 
respectively. Therefore, the successful complexation of PTX in γ-CD can be 
proved by the appearance of the 1H NMR peaks and UV-vis absorption when 
the complexes are dissolved in D2O or water. Figure 5.2 shows the 1H NMR 
spectra of the inclusion complexes γ-CD-OEI/PTX, γ-CD-OEI-FA/PTX, and 
γ-CD-OEI-SS-FA/PTX in comparison with γ-CD-OEI and γ-CD-OEI-SS-FA. 
The typical signals of PTX phenyl rings can be observed at δ 7.2 – 8.2, and the 
stoichiometry can be calculated by comparing the integral strengths of PTX 
phenyl rings and OEI arms. As a result, one PTX molecule is included in one 
γ-CD cavity, corresponding to 13.0, 11.5, and 10.4% loading level of PTX in 
the inclusion complexes. To further confirm the formation of the inclusion 
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inclusion complexes, including γ-CD-OEI/PTX, γ-CD-OEI-FA/PTX, and 
γ-CD-OEI-SS-FA/PTX, have obvious absorption peaks at 230 nm, indicating 
the successful complexation of PTX in the γ-CD cavity. 
 
Figure 5.3. UV-vis spectra of γ-CD-OEI, γ-CD-OEI/PTX, γ-CD-OEI-FA, 
γ-CD-OEI-FA/PTX, γ-CD-OEI-SS-FA, and γ-CD-OEI-SS-FA/PTX at 0.1 
mg/mL in H2O. The arrow indicates UV absorption of PTX at 230 nm. 
5.3.2. Formation of Polyplexes with pDNA 
 
Figure 5.4. Electrophoretic mobility of pDNA in the polyplexes formed with 
PEI (a), -CD-OEI/PTX (b), -CD-OEI-FA/PTX (c), and 
-CD-OEI-SS-FA/PTX (d). The arrows indicate the N/P ratios where the DNA 
mobility is completely retarded. 
The binding ability of the γ-CD-OEI/PTX, γ-CD-OEI-FA/PTX, and 
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analyzed by agarose gel electrophoresis in comparison with PEI (25 kDa). 
Figure 5.4 shows that PEI, γ-CD-OEI/PTX, γ-CD-OEI-FA/PTX, and 
γ-CD-OEI-SS-FA/PTX entirely compacted pDNA at N/P ratios of 2.5, 2.5, 
3.0, and 2.5, respectively. The results indicate that the binding ability of the 
inclusion complexes is strong, which is similar to that of PEI, as well as to that 
of the PTX-free γ-CD-OEI, γ-CD-OEI-FA, and γ-CD-OEI-SS-FA 50. 
 
 
Figure 5.5. Particle size (a) and zeta potential (b) of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI/PTX, -CD-OEI-FA, -CD-OEI-FA/PTX, 
-CD-OEI-SS-FA, and -CD-OEI-SS-FA/PTX at various N/P ratios. 
Figure 5.5 displays the particle size and zeta potential of the pDNA 
polyplexes with PEI, the three precursors (γ-CD-OEI, γ-CD-OEI-FA, and 
γ-CD-OEI-SS-FA), and the inclusion complexes (γ-CD-OEI/PTX, 
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shown in Figure 5.5a, all the cationic polymers efficiently compact pDNA into 
small nanoparticles with particle sizes around 70 to 110 nm. Their surface 
charge density in terms of zeta potential ranges from 25 to 36 mV as shown in 
Figure 5.5b. The formation of inclusion complexes with PTX did not 




Figure 5.6. Cell viability assay in KB cells. The KB cells were treated with PEI 
(25 kDa), -CD-OEI, -CD-OEI/PTX, -CD-OEI-FA, -CD-OEI-FA/PTX, 
-CD-OEI-SS-FA, -CD-OEI-SS-FA/PTX, and physical mixture of 
-CD-OEI-SS-FA and PTX (denoted by -CD-OEI-SS-FA + PTX) at various 
concentrations for 24 hours in FA-free RPMI 1640 medium. Data represent 
mean  standard deviation (n = 4). 
Figure 5.6 shows the cell cytotoxicity results in KB cells. As a result, all 
the PTX-free γ-CD-OEI, γ-CD-OEI-FA, and γ-CD-OEI-SS-FA showed lower 
cytotoxicity than PEI because the introduction of CD ring could decrease the 
cytotoxicity. The formation of inclusion complexes with PTX considerably 
increased the cytotoxicity of these compounds, obviously due to the 
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PTX with DMSO as solubilizer showed much higher cytotoxicity due to the 
free PTX that is available immediately. 
5.3.4. In vitro Luciferase Gene Transfection 
 
 
Figure 5.7. In vitro gene transfection efficiency of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI-FA, -CD-OEI-SS-FA, -CD-OEI/PTX, 
-CD-OEI-FA/PTX, -CD-OEI-SS-FA/PTX, and physical mixture of 
-CD-OEI-SS-FA and PTX (denoted by -CD-OEI-SS-FA + PTX) at different 
N/P ratios in KB cells (a) and A549 cells (b) in FA-free RPMI 1640 medium. 
Data represent mean  standard deviation (*P < 0.005, n = 4). 
The FR-mediated targeted gene delivery and enhanced gene expression by 
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assay in FR-positive KB cells and FR-negative A549 cells. The gene 
transfection efficiency of γ-CD-OEI-SS-FA/PTX in KB cells (Figure 5.7a) and 
A549 cells (Figure 5.7b) was evaluated in comparison with PEI, γ-CD-OEI, 
γ-CD-OEI-FA, γ-CD-OEI-SS-FA, γ-CD-OEI/PTX, γ-CD-OEI-FA/PTX, and 
physical mixture of γ-CD-OEI-SS-FA and PTX in FA-free RPMI 1640 
medium. The structural difference of γ-CD-OEI-SS-FA and γ-CD-OEI-FA is 
that the former possesses a disulfide linker between FA and γ-CD-OEI. This 
disulfide linker can be reduced by glutathione (GSH) after FR-mediated 
endocytosis and then the FR could be readily released and recycled to cell 
membrane. As discussed in our previous work, the FA-targeted delivery 
combined with the smart FR-recycling function can achieve a significant 
enhancement of gene expression.50 The cytotoxicity of the PTX inclusion 
complexes was obvious at N/P ratio of 40 and 50, so the gene expression data 
were not shown in Figure 5.7. 
In FR-positive KB cells (Figure 5.7a), co-delivery of PTX could further 
enhance the gene transfection efficiency following the order 
γ-CD-OEI-SS-FA/PTX > γ-CD-OEI-FA/PTX > γ-CD-OEI/PTX. For 
PTX-free carriers, the gene transfection efficiency followed a similar order 
γ-CD-OEI-SS-FA > γ-CD-OEI-FA > γ-CD-OEI. The gene transfection 
efficiency of γ-CD-OEI-SS-FA/PTX was constantly higher than that of PEI 
(25 kDa) and all the other carriers. Generally, all the three PTX-complexed 
gene carriers showed significantly higher gene transfection efficiency at low 
N/P ratios ranging from 10 to 20 than that of their PTX-free counterparts. 
According to the cell viability results, these PTX-complexed carriers had 
comparatively high cytotoxicity due to the complexed PTX. In this work, the 
increase of N/P ratios to high level resulted in a decrease of gene transfection 
efficiency because of the high cytotoxicity of PTX. So, we focus our 
discussion on the gene transfection experiments involving these 
PTX-complexed gene carriers at low N/P ratio range from 10 to 30. At N/P 
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ratio of 15, γ-CD-OEI-SS-FA/PTX showed optimal gene transfection 
efficiency, which was also significantly higher than that of γ-CD-OEI-SS-FA, 
γ-CD-OEI-FA/PTX, γ-CD-OEI-FA, γ-CD-OEI/PTX, and γ-CD-OEI, by 
8-fold, 1-fold, 10-fold, 6-fold, and 21-fold, respectively. Further, even 
γ-CD-OEI/PTX without target group showed considerably enhanced gene 
transfection efficiency, which is 4-fold higher than that of γ-CD-OEI. These 
results proved the synergistic or combined effect of co-delivery of PTX with 
DNA to enhance the gene transfection, as well as the enhancement effects 
induced by the FA-targeted group and the reducible disulfide linker. In 
contrast, in FR-negative A549 cells (Figure 5.7b), the FA and disulfide linker 
showed no enhancement effect on gene expression due to the lack of 
FR-mediated endocytosis, and the complexation of PTX also had no 
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Figure 5.8. In vitro gene transfection efficiency of the pDNA polyplexes with 
by PEI (25 kDa), -CD-OEI, -CD-OEI-FA, -CD-OEI-SS-FA, -CD-OEI/PTX, 
-CD-OEI-FA/PTX, -CD-OEI-SS-FA/PTX, and physical mixture of 
-CD-OEI-SS-FA and PTX (denoted by -CD-OEI-SS-FA + PTX) at N/P ratio 
of 15 in KB cells (a) and A549 cells (b) in the absence and presence of 0.001 g/L 
of FA in the culture medium. Data represent mean  standard deviation (*P < 
0.005, n = 4). 
To further demonstrate the effects of the supramolecular self-assembly 
and the FA group attached to the carrier, FA competition tests were carried out 
by comparison of gene transfection efficiency in the absence and presence of 
FA in the cell culture medium. As shown in Figure 5.8a, the gene transfection 
efficiency of both FA-modified carriers (γ-CD-OEI-FA, and 
γ-CD-OEI-SS-FA) and their PTX-complexed self-assemblies 
(γ-CD-OEI-FA/PTX, and γ-CD-OEI-SS-FA/PTX) was reduced when the 
FR-positive KB cells were treated with FA-containing culture medium. In 
contrast, other carriers without FA group, such as PEI, γ-CD-OEI, and 
γ-CD-OEI/PTX had almost no difference in the absence and presence of FA in 
the culture medium. In addition, although the effect was considerably 
weakened because of the competition of FRs by free FA in the FA-containing 
medium, the PTX-complexed self-assembly carriers (γ-CD-OEI-SS-FA/PTX 
and γ-CD-OEI-FA/PTX) still had higher gene transfection efficiency than all 
other carriers. The physical mixture of γ-CD-OEI-SS-FA and PTX showed 
higher gene transfection than γ-CD-OEI-SS-FA, but lower than 
γ-CD-OEI-SS-FA/PTX and γ-CD-OEI-FA/PTX. Moreover, the gene 
transfection efficiency for this physical mixture system was also reduced when 
the FA-containing medium was applied. These results indicate that the FA 
group in γ-CD-OEI-SS-FA was an important factor to improve the gene 
transfection, and the PTX-complexed self-assembly system showed double 
effects in enhancing the gene transfection efficiency. In contrast, when the 
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experiments were done in FR-negative A549 cells, the transfection efficiency 
for each carrier showed no difference in the absence and presence of FA in the 
culture medium (Figure 5.8b). Also, generally all γ-CD-based carriers with or 
without FA modification showed low gene transfection efficiency at this low 
N/P ratio of 15, which is much lower than that of PEI. FA-modified carriers in 
FR-negative A549 cells showed low transfection efficiency due to the lack of 
FR-mediated endocytosis effect. There was also no PTX co-delivery effect at 
the low N/P ratio of 15 in FR-negative A549 cells, probably due to the 
generally low gene transfection efficiency. 
 
Figure 5.9. In vitro gene transfection efficiency of the pDNA polyplexes with 
PEI (25 kDa), -CD-OEI, -CD-OEI-FA, -CD-OEI-SS-FA, -CD-OEI/PTX, 
-CD-OEI-FA/PTX, -CD-OEI-SS-FA/PTX, and physical mixture of 
-CD-OEI-SS-FA and PTX (denoted by -CD-OEI-SS-FA + PTX) at N/P ratio 
of 15 in KB cells in the absence and presence of 250 μM of BSO in the culture 
medium. Data represent mean  standard deviation (*P < 0.005, n = 4) 
BSO can reduce the intracellular glutathione concentration and inhibit the 
reduction of disulfide linker52, 53.50, 51 At the presence of BSO, the effect of the 
disulfide linker in the disulfide-containing carrier systems will be weakened. 
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systems including γ-CD-OEI-SS-FA, its PTX-complexed 
γ-CD-OEI-SS-FA/PTX, and the physical mixture of γ-CD-OEI-SS-FA and 
PTX was significantly decreased when the KB cells were treated with 
BSO-containing medium. In contrast, the systems without disulfide bond 
showed almost no changes. We previously reported that the reducible disulfide 
linker in the γ-CD-OEI-SS-FA system can lead to the detachment of the FA 
groups from the polymeric carrier after the FR-mediated endocytosis, which 
results in the release of the bound FRs followed by the recycling of the FRs 
from the cytosol onto the cell membrane surface, facilitating continuous 
FR-mediated endocytosis to achieve enhanced gene transfection.50 
Figure 5.10 gives the confocal microscopy images showing the cellular 
uptake of the pDNA polyplexes with all γ-CD-based carriers and their 
PTX-complexed self-assemblies. PTX was labeled with FITC giving green 
fluorescence and the cationic γ-CD-based carriers with rhodamine that is red. 
After treating the FR-positive KB cells with the pRL-CMV polyplexes for 2 
hours in FA-free medium, the cellular uptake rate follows an order 
γ-CD-OEI-SS-FA/PTX = γ-CD-OEI-SS-FA > γ-CD-OEI-FA/PTX = 
γ-CD-OEI-FA > γ-CD-OEI/PTX = γ-CD-OEI, which is consistent with the 
results of gene transfection experiments. Most of the green and red 
fluorescence polyplexes appeared overlapped. Some free green fluorescence 
dots could also be observed due to the release of the complexed PTX, which 
explains the cell viability results that all the three PTX-complexed 
self-assembly systems had higher cytotoxicity. 
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Figure 5.10. Confocal microscopy images of the KB cells transfected by the 
pDNA polyplexes with -CD-OEI-Rhd (a), -CD-OEI-Rhd/PTX-FITC (b), 
-CD-OEI-FA-Rhd (c), -CD-OEI-FA-Rhd/PTX-FITC (d), 
-CD-OEI-SS-FA-Rhd (e), -CD-OEI-SS-FA-Rhd/PTX-FITC (f), and 
-CD-OEI-SS-FA/PTX-FITC (g) at N/P ratio of 15 in FA-free RPMI 1640 
medium. PTX and -CD-OEI derivatives were labeled with FITC (green) and 
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5.3.5. Delivery of Wild Type p53 Gene for Cancer Cell Apoptosis 
The protein encoded by p53 gene is a common tumor suppressor which 
plays a critical role in diverse cellular pathways, such as DNA repair, 
regulation of cell cycle, and cell apoptosis.54 It has been reported that p53 
gene is mutated nearly in 50% of human cancers. Mutant p53 gene loses its 
ability to control cell cycle and cell apoptosis, resulting in tumor growth. 
Hence, functional restoration of wild type p53 gene in cancer cells can 
suppress cell proliferation and stimulate apoptosis. This was evidenced by the 
fact that adenovirus-mediated p53 gene delivery showed tumor regression in 
clinical trials, although this method has been limited in intra-tumor injection.55 
 
Figure 5.11. Representative cell cycle diagrams of KB cells transfected with 
pCMV-p53 mediated by -CD-OEI/PTX (a), -CD-OEI-FA/PTX (b), 
-CD-OEI-SS-FA/PTX (c), and transfected with pCMV-p53mt135 mediated by 
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-CD-OEI/PTX (d), -CD-OEI-FA/PTX (e), and -CD-OEI-SS-FA/PTX (f) at 
N/P ratio of 15 in FA-free RPMI 1640 medium. 
Herein we have applied the multifunctional supramolecular self-assembly 
drug and gene co-carrier for delivery of wild type p53 gene into KB cells to 
efficiently control the cancer cell apoptosis. For this purpose, two plasmids 
pCMV-p53 and pCMV-p53mt135 were used. pCMV-p53 expresses the 
wild-type p53 tumor suppression protein and pCMV-p53mt135 expresses a 
mutant p53 protein that does not have tumor suppression effect, which is used 
as negative control. 
Figure 5.11 shows the cell cycle diagrams of FR-positive KB cells 
transfected with pCMV-p53 and pCMV-p53mt135 genes with different carrier 
systems. Table 5.1 and Table 5.2 summarize the cell cycle analysis results for 
FR-positive KB cells and FR-negative cells transfected with pCMV-p53 and 
pCMV-p53mt135 genes mediated by different carrier systems. In FR-positive 
KB cells, the PTX-complexed γ-CD-OEI-SS-FA/PTX self-assembly system 
resulted in remarkably larger cell population at sub G1 phase (23.48%) than 
any other carrier systems (Figure 5.11c, Table 5.1). Moreover, the G2/M phase 
for these KB cells was 31.54%, indicating that the PTX-induced microtubule 
stabilization led to G2/M cell cycle arrest. As also supported by our luciferase 
gene transfection results, we can reasonably conclude that the very efficient 
p53 gene delivery mediated by the γ-CD-OEI-SS-FA/PTX self-assembly 
system was a result from the combined and synergistic effects of the 
PTX-enhanced gene transfection, the FA-targeted delivery, and the disulfide 
linker mediated FR-recycling. 
Table 5.1. Cell cycle analysis results of FR-positive KB cells transfected with 
pCMV-p53 and pCMV-p53mt135 mediated by PEI (25 KDa), -CD-OEI, 
-CD-OEI-FA, -CD-OEI-SS-FA, -CD-OEI/PTX, -CD-OEI-FA/PTX, 
-CD-OEI-SS-FA/PTX, and physical mixture of -CD-OEI-SS-FA and PTX at 
N/P ratio of 15 in FA-free RPMI 1640 medium. 
 
Chapter 5. Cyclodextrins for Drug and Gene Co-delivery 
124 
 
Table 5.2. Cell cycle analysis results of FR-negative A549 cells transfected 
with pCMV-p53 and pCMV-p53mt135 mediated by PEI (25 KDa), -CD-OEI, 
-CD-OEI-FA, -CD-OEI-SS-FA, -CD-OEI/PTX, -CD-OEI-FA/PTX, 
-CD-OEI-SS-FA/PTX, and physical mixture of -CD-OEI-SS-FA and PTX at 
N/P ratio of 15 in FA-free RPMI 1640 medium. 
 
In comparison, when the mutant pCMV-p53mt135 was used in KB cells, 
all carrier systems showed no effects on the cell apoptosis and G2/M cell cycle 
arrest induced by PTX (Figure 5.11, Table 5.1), since pCMV-p53mt135 only 
expresses a mutant p53 protein that does not have tumor suppression effect. 
When both pCMV-p53 and pCMV-p53mt135 were used in FR-negative A549 
cells, also all carrier systems showed no effects on the cell apoptosis and 
G2/M cell cycle arrest induced by PTX (Table 5.2), since there had no effects 
of the FA-targeted delivery, and the disulfide linker mediated FR-recycling. 
Polymers
pCMV-p53 pCMV-p53mt135
sub G1 G0/G1 S G2/M sub G1 G0/G1 S G2/M
PEI 1.39 71.33 11.06 16.18 1.65 65.23 14.98 17.84 
γ-CD-OEI 1.62 67.69 12.10 18.17 0.77 59.50 15.84 22.78 
γ-CD-OEI/PTX 1.15 71.46 12.80 14.25 0.54 64.19 15.97 18.52 
γ-CD-OEI-FA 1.17 70.02 13.59 14.99 0.73 62.94 17.38 18.13 
γ-CD-OEI-FA/PTX 9.73 50.40 15.60 23.14 1.08 63.33 14.69 20.33 
γ-CD-OEI-SS-FA 1.90 71.14 13.50 13.33 0.81 61.30 16.11 20.67 
γ-CD-OEI-SS-FA/PTX 23.48 29.41 11.91 31.54 5.10 54.80 16.96 21.28 
γ-CD-OEI-SS-FA+PTX 0.92 71.54 12.42 15.05 0.71 64.07 16.28 18.21 
Polymers
pCMV-p53 pCMV-p53mt135
sub G1 G0/G1 S G2/M sub G1 G0/G1 S G2/M
PEI 0.53 57.97 12.59 27.45 0.51 58.66 13.15 26.59 
γ-CD-OEI 0.42 53.81 13.65 30.23 0.87 54.66 13.99 28.55 
γ-CD-OEI/PTX 0.29 52.08 13.58 32.06 0.38 53.96 12.78 31.18 
γ-CD-OEI-FA 0.44 54.95 12.77 30.24 0.37 57.34 13.10 27.63 
γ-CD-OEI-FA/PTX 0.39 55.48 13.48 28.73 0.32 55.36 12.77 29.78 
γ-CD-OEI-SS-FA 0.35 52.45 14.55 29.92 0.44 56.39 13.34 28.12 
γ-CD-OEI-SS-FA/PTX 0.32 51.62 13.58 31.82 0.55 54.48 13.30 29.75 
γ-CD-OEI-SS-FA+PTX 9.16 15.39 14.34 60.62 10.96 13.95 10.85 64.07 
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5.4. Conclusions 
Self-assembled inclusion complex between the star-shaped cationic polymer 
γ-CD-OEI-SS-FA and anticancer drug PTX was prepared, as the precursor of 
the multifunctional supramolecular self-assembly co-delivery system for PTX 
and pDNA. PTX was included in the γ-CD ring of γ-CD-OEI-SS-FA to form a 
1:1 complex, corresponding to a 10.4% loading level of PTX. The 
γ-CD-OEI-SS-FA/PTX complex had good solubility in water, although PTX is 
water-insoluble. The γ-CD-OEI-SS-FA/PTX complex could form polyplexes 
with pDNA to give positively charged nanoparticles with size ranging from 70 
to 110 nm, forming the multifunctional supramolecular self-assembly 
co-delivery system for PTX and pDNA. 
The gene transfection experiments using luciferase marker gene were 
carried out in FR-positive KB cells and FR-negative A549 cells under various 
conditions. The results showed that the FA-targeted delivery induced higher 
gene transfection efficiency in the FR-positive KB cells. In addition, the 
reducible disulfide linker in the γ-CD-OEI-SS-FA/PTX self-assembly system 
led to the detachment of the FA groups from the carrier after the FR-mediated 
endocytosis, which resulted in the release of the bound FRs followed by the 
recycling of the FRs from the cytosol onto the cell membrane surface, 
facilitating continuous FR-mediated endocytosis to achieve the enhanced gene 
transfection. Moreover, the complexed PTX was co-delivered to the cells with 
pDNA, and the co-delivered PTX further enhanced the gene transfection even 
at a low N/P ratio of 15 in the FR-positive KB cells.  
Finally, the γ-CD-OEI-SS-FA/PTX self-assembly co-delivery system was 
used to deliver wild-type p53 gene in KB cells. From the cell cycle analysis, 
the transfected KB cells showed large cell population at sub G1 and G2/M 
phases, indicating the efficient delivery of p53 gene that induced significant 
cell apoptosis. The data in this study have demonstrated that the 
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multifunctional γ-CD-OEI-SS-FA/PTX self-assembly co-delivery system 
showed the combined and synergistic effects of the PTX-enhanced gene 
transfection, the FA-targeted delivery, and the redox-sensitive FR-recycling. 
The multifunctional synergistic effects resulted in the very effective deliver of 
wild-type p53 gene into FR-overexpressed KB cancer cells at low N/P ratios 
to induce an efficient cell apoptosis. Therefore, the novel multifunctional 
supramolecular self-assembly delivery system may be a promising candidate 
for potential cancer therapeutic application. 
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CHAPTER 6 CONCLUSIONS AND FUTURE 
WORK 
6.1. Conclusions 
This research studied on synthesis of novel multi-functional 
cyclodextrin-based cationic star polymers for drug and gene delivery. 
Generally, the host-guest structure between cyclodextrin (CD) ring with 
hydrophobic cavity and hydrophobic anticancer drug was synthesized to alter 
the solubility and cytotoxicity of drug. Cyclodextrin-oligoethylenimines 
(CD-OEIs) modified with targeted groups and biodegradable linkers were 
prepared for site-specific and enhanced gene delivery. Moreover, the CD ring 
was included anticancer drug for potential drug and gene co-delivery. These 
CD-based cationic polymers have potential applications in cancer therapy. 
In detail, this study reported a synthesis of OEI-conjugated α-, β-, and 
γ-CD as a carrier for anticancer drug paclitaxel (PTX). As a result, structure 
modification by OEI significantly increase the water solubility of β-CD, which 
are widely used in oral drug delivery but limited by its poor water solubility. 
Moreover, the formation of inclusion complexes remarkably increase water 
solubility of PTX with 146,149-fold higher than the mother drug. In addition, 
the α-CD derivative also demonstrated up to 30,956-fold higher water 
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solubility than pure PTX. As we known, it is the best α-CD-based carrier for 
PTX delivery. Furthermore, the anticancer ability is still maintained. 
This study has expanded the strategy of folic acid (FA)-targeted delivery 
by combining the smart folate receptor (FR)-recycling function to achieve the 
significant enhancement of gene expression. We synthesized a new star-shaped 
cationic polymer consists of a -cyclodextrin (-CD) core and multiple 
oligoethylenimine (OEI) arms, conjugating with folic acid (FA) and 
incorporating with a biodegradable disulfide bond between polymer and target 
group for efficient targeted gene delivery. The synthesized cationic polymer, 
named γ-CD-OEI-SS-FA, could be efficiently cleaved under reductive 
condition similar to intracellular environment that reduces the disulfide linker, 
and then conjugated FA was readily released. The γ-CD-OEI-SS-FA polymers 
have good DNA condensation ability and lower cytotoxicity than PEI (25 
kDa). Moreover, the γ-CD-OEI-SS-FA polymer can efficiently deliver pDNA 
into FR-positive cells through FR-mediated cellular uptake. The enhancement 
effects by structure modification of FA and disulfide bond were further 
demonstrated by FA competition and disulfide inhibitory tests. 
Further studies focus on the drug and gene co-delivery to take advantage 
of the hydrophobic cavity of cyclodextrin. In detail, the inclusion complex 
between the star-shaped cationic γ-CD-OEI-SS-FA polymer and anticancer 
drug PTX was synthesized. The inclusion complex was stable in aqueous with 
12% loading efficiency of PTX. The targeted delivery and FR recycling effect 
inducing by disulfide linker can be maintained. Moreover, introduction of 
PTX significantly increase the gene expression in luciferase assay and reduce 
the administration of polymer. Co-delivery of PTX and wild-type p53 gene 
with the cationic polymer shows large cell population at sub G1 and G2/M 
phase, demonstrating cell apoptosis and PTX-induced microtubule 
stabilization. 
In general, the research of CD-OEI for PTX delivery greatly expands the 
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application of drug delivery using CDs. The cationic γ-CD-OEI-SS-FA carrier 
with FA-targeted and biodegradable capability may be a promising efficient 
gene delivery vector. Co-delivery of drug and gene has significant synergistic 
effect and it could be an efficient strategy for potential cancer gene therapy. 
6.2. Future Work 
As mentioned in the literature review, the unique structure of polyrotaxane 
has many interesting advantages for potential drug and gene delivery, such as 
the highly mobility of threaded cyclodextrins that could enhance the 
ligand-receptor interactions, the dethreading ability induced by cleavage of 
terminal groups may contribute to controlled release, and the easy chemical 
modification of threaded cyclodextrins. Synthesis of cationic polyroataxanes 
with target group folic acid and disulfide linker are promising structure that 
can keep the target effect and enhance the interaction with folate receptor on 
the malignant cell surface. 
Many drug and gene delivery vectors suffered non-specifically adherent to 
normal cells and extracellular components, such as serum protein. This 
problem can be alleviated by shielding of the particle surface with hydrophilic 
uncharged molecule, such as PEG1 or poly [N-2-(hydroxypropyl) 
methacrylamine] (PHPMA)2. The shield procedure can additionally reduce 
toxicity, prevent aggregation, and extend the half-life of polyplexes.3 
Therefore, structure modification with PEGylation may be promising tools to 
overcome this obstacle, and our synthesized cationic polymers still have many 
sites for further modification. 
Although many types of folate conjugates have been tested by kinds of 
animal models, only six of folate-conjugated drugs have already entered clinic 
trials.4-9 The parameters and barriers for in vivo delivery are higher and more 
sophisticates than those encountered in vitro, so it would be necessary to 
demonstrate the effect of drug and gene delivery carriers in animal test. 
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In general, additional improvements and experiments to improve the gene 
transfection efficiency and to prove the stability and efficiency in systemic 
administration in vivo are better to be investigated in future studies. 
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